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A COMPARATIVE STUDY ON ACCURACY OF COCKCROFT GAULT AND 
MDRD FORMULAE WITH 24 HOUR URINE CREATININE CLEARANCE IN 
ESTIMATING GLOMERULAR FILTRATION RATE 
 
Abstract: 
 Estimation of the glomerular filtration rate (GFR) is important in clinical 
practice that too in intensive care setting. Most of the antibiotics and drugs that 
are used in ICU setting are excreted via the kidney. The MDRD formula and 
Cockcroft Gault equation are most commonly used to calculate GFR. 
Usefulness of these formulas in clinical setting is dependent on precision and 
bias. So this study is designed to evaluate these formulas with 24 hour urine 
creatinine clearance in critically ill patients by calculating correlation 
coefficient. Materials and methods: This study was conducted in 100 adult 
patients of Govt, Rajaji, hospital, Madurai. We estimated Creatinine Clearance 
by CG and MDRD formula and measured GFR by 24 hrs urine creatinine 
clearance. Bland Altman plot was used to find the difference between the paired 
observations. Results: The mean GFR measured by 24 hours urine creatinine 
clearance was 44.75ml/min/1.73m2 (95% CI: 41.13 to 48.37). The mean 
glomerular filtration rate calculated by Cockcroft-Gault formula was 
56.48ml/min/1.73m2 (95%CI: 52.45 to 60.51) and by MDRD formula was 
48.71ml/min/m2 (95% CI: 44.80 to 52.62). Correlation coefficient for 
comparison of CG formula/24 hour urine creatinine clearance and MDRD/24 
hour urine clearance were 0.90956 with p value of <0.0001 and 0.9303 with p 
value of <0.0001 respectively. Bias is defined as the mean difference between 
calculated and measured GFR. In our study bias was 11.73ml/min for 
Cockcroft-Gault equation and 3.961ml/min for MDRD equation. This indicates 
overestimation of glomerular filtration rate by these two formulas.  
Conclusion: C-G and MDRD equations can be an alternative to the CrCl test 
for assessing GFR, thus avoiding the need for the cumbersome and expensive 
GFR test. The MDRD formula had greater validity than the C-G equation. 
Key words: Glomerular filtration rate, Cockcroft-Gault formula (C-G), 
Modification Diet in Renal Disease Formula (MDRD), bland Altman analysis. 
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INTRODUCTION 
Estimation of the glomerular filtration rate is important in clinical 
practice that too in intensive care setting. Most of antibiotics and drugs that 
are used in ICU setting are excreted via the kidney. Usually in research 
GFR is measured by substances completely filtered by the glomerulus 
without tubular secretion or tubular reabsorption. Commonly used 
substances for this purpose are inulin, isotopes such as Technetium‑ 99m 
diethyl triamine penta-acetic acid (Tc99m DTPA) or chromium 51 
Ethylene diamine tetraacetic acids (Cr51 EDTA), iohexol or iothalmate
1
. 
These methods are not possible in ICU setup particularly in 
developing countries like India. So serum creatinine is used to calculate 
GFR. But serum creatinine is dependent on age, sex, muscle mass and type 
of food consumed. So GFR based on serum creatinine is not accurate to 
decide about drug dosage and treatment. 
GFR calculation by 24 urine creatinine clearance may correct some 
of the errors due to muscle mass and creatinine generation. But 
measurement of 24 hour creatinine clearance is not at all possible in 
treatment decision, because we have to wait for at least 24 hours to get the 
results
1
. In the meantime kidney function may change. So lot of formulas 
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was devised to calculate GFR by using serum creatinine, age, sex and body 
weight. 
The MDRD formula and Cockcroft Gault equation are most 
commonly used to calculate GFR. Cockcroft Gault formula derived from 
group of white men, based on serum creatinine and age. Females are not 
included while deriving this formula. Based on expert opinion GFR is 
reduced by 15% for them. MDRD formula derived from group of 
outpatients. Some of the studies evaluated these formulas in critically ill 
patients but with normal creatinine. So application these formulas derived 
from stable patient needs to be evaluated before applying into critically ill 
patients. 
 There are some unique issues with these patients in their 
hemodynamic instability, rapid change in kidney function, protein catabolic 
state and battery of medication. These are also affecting the GFR 
calculation in these patients. Usefulness of these formulas in clinical setting 
is dependent on precision and bias. So this study is designed to evaluate 
these formulas in critically ill patients by calculating correlation 
coefficient
1
. 
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AIMS AND OBJECTIVES 
 To compare the glomerular filtration rate calculated by Cockcroft-
Gault and MDRD formula with glomerular filtration rate measured 
by 24 hours urine creatinine clearance. 
 By calculating bias and correlation coefficient, to decide about 
usefulness of these formulas in critical care setting. 
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REVIEW OF LITERATURE 
NORMAL ANATOMY AND PHYSIOLOGY OF KIDNEY 
The main function of the kidney is to maintain internal homeostasis 
and giving suitable environment for cellular metabolism and cellular 
function. Kidneys achieve these by excreting metabolic waste products, 
balancing solute and water transport, conserving nutrients and also by 
maintaining acid-base balance. Kidneys also functioning as a endocrine 
organ by secreting renin, erythropoietin and 1,25-dihydroxy cholecalciferol 
(vitamin D) which regulates blood pressure and electrolyte balance, RBC 
production and calcium metabolism and bone mineral density respectively
2
. 
ANATOMY 
Kidneys are two paired organs situated in the retroperitoneal space 
along the sides of the vertebral column. They are extending between T12 
vertebra to L3 vertebra. Because of liver right kidney situated slightly 
lower than the left kidney. Each kidney is weighing approximately 125 to 
175 grams in male and 115 to 155 grams in female. Length of the kidney is 
11 to 12 centimeters, width is 5 to 7 centimeters and thickness is 
approximately 3 centimeters
2
. Renal artery, renal vein, ureters lymphatics 
and nerve plexus enters kidneys via the renal hilum which is situated along 
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the medial surface of the kidney. There is a renal capsule which surrounds 
the kidney. 
After entering into hilum renal artery divides into anterior and 
posterior branches. Anterior branch divides into three lobar or segmental 
arteries and supplies the anterior surface of the kidney. The posterior 
branch of the renal artery supplies the posterior surface of the kidney and 
very rarely it gives an apical branch. These are end arteries; there are no 
anastomoses between these arteries. 
Kidney consists of outer cortex and inner medulla. There are 8 to 18 
renal pyramids in each kidney which are located in the medulla. The apices 
of the renal pyramid are towards the renal pelvis and forms papilla; bases 
of the pyramids are towards the cortex. Collecting duct opens into papilla. 
Cortex contains all the glomeruli and portions of the tubules. The renal 
cortex is 1 cm thick and extends between the pyramids to form the renal 
columns of Bertini. From the base of the renal pyramid, at the 
corticomedullary junction, longitudinal elements termed the "medullary 
rays” extend into the cortex. These medullary rays are formed by collecting 
ducts, proximal and distal tubules
2
. 
Renal pelvis represents upper dilated end of ureter which is lined by 
transitional epithelium. Two or three major calyces extend from the renal 
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pelvis, from which several minor calyces extends towards the renal papilla 
and drain the urine. Lower part of renal pelvis continued as ureter and 
opens into the bladder. The renal pelvis represents the upper urinary tract 
and is lined by transitional epithelium.  The major calyces which is two or 
three in number, extends from renal pelvis. From major calyces, several 
minor calyces extend toward the papillae and drain the urine. The ureters 
are 28 to 34 cm in length, arise from lower part of the renal pelvis and open 
into the bladder. The smooth muscle is present in the walls of ureters 
produces peristaltic movement. With this movement, urine from the kidney 
drains into the bladder. 
THE NEPHRON 
The nephron is the functional unit of the kidney, each kidney consist 
approximately 1.2 million nephrons. The parts of the nephron are the 
glomerulus, proximal tubule, loop of Henle, distal tubule, and the 
collecting duct. The nephron develops from metanephric blastema. 
Embryologically collecting ducts develops from the ureteric bud.  
Nephrons are divided into two groups based on length of loop of 
henle. The loop of Henle consists of thin descending limb and thick 
ascending limb. Cortical nephrons have short loop of henle and juxta 
medullary nephrons have long loops. 
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GLOMERULUS 
Glomerulus consists of tuft of capillaries lined by endothelial cells, 
mesangial cells with mesangial matrix, the visceral and parietal layer of 
Bowman’s capsule with basement membrane. Bowman's   space is situated 
between the visceral and parietal epithelial layers. The diameter of the 
glomerulus is around 200 µm
3
. The glomerulus produces the ultra-filtrate 
of plasma. The filtering unit consists of endothelium, basement membrane, 
and the foot processes of the visceral epithelial cells. 
Capillaries in the glomerulus is lined by fenestrated endothelial cells, 
these fenestrations are surrounded by intermediate filaments and 
microtubules. This glomerulus endothelium has negative charge; this is 
provided by Podocalyxin. Nitric oxide (vasodilator) and endothelin-1 are 
synthesized by glomerular endothelial cells. VEGF receptors are seen in the 
endothelial cells
3
. VEGF is produced by visceral epithelial cells and it 
increases permeability of endothelial cells by increasing the formation of 
endothelial fenestrations and also VEGF is essential for survival and repair 
of endothelial cell in glomerular diseases. Each epithelial layer in the 
glomerulus has unique structural properties that allow components of the 
blood to pass through with the exception of blood cells and plasma proteins 
of molecular weight greater than 70,000. The endothelial cells are the 
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barrier to prevent the passage of blood components from reaching 
Bowman's space. 
 
 
VISCERAL EPITHELIAL CELLS 
The distance between two visceral epithelial cell foot processes is 25 
to 60 nm. This is filtration slit and is covered by a thin membrane called 
filtration slit membrane. A central filament is seen in the filtration slit 
diaphragm. Nephrin is the main constituent of the filtration barrier. NPHS1 
gene located in the chromosome 19 codes this nephrin; Mutation of NPHS1 
is noticed in congenital nephrotic syndrome of the Finnish type
5
. Nephrin is 
seen in the visceral epithelial cells particularly in the slit diaphragm. 
    Fig-1 Normal glomerulus 
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Deletion of CD2AP, which binds the nephrin to the cytoskeleton, is 
responsible for congenital nephrotic syndrome. Mutation of the Podocin; a 
membrane protein that is seen in filtration barrier is responsible for familial 
steroid-resistant nephrotic syndrome
5
. The foot processes are replaced by 
cytoplasmic band which is termed as effacement of foot process. 
Podoplanin maintains shape of foot process. The visceral epithelial cells are 
responsible for the production and maintenance of the filtration membrane. 
PARIETAL EPITHELIAL CELLS 
Parietal epithelial cells are squamous epithelial cells. Recent 
evidences suggest that they are progenitors of podocytes. After injury to 
podocytes these parietal epithelial cells regenerates and forms podocytes. 
They also implicated in some form of proliferative form of 
glomerulonephritis. 
MESANGIAL CELLS 
Irregularly shaped mesangial cells and its matrix constitute the 
mesangium. Mesangial cells have dense nucleus and elongated cytoplasmic 
processes. These processes consist of microfilaments such as actin, actinin 
and myosin. These cells bridge the gap between glomerulus and basement 
membrane and prevent distension of capillaries. Mesangial matrix 
composed of glycosaminoglycans and collagen
4
. Mesangial cells are 
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specialized form of pericyte; having many characteristics of smooth muscle 
cells. They are providing support to glomerular capillaries, regulates 
glomerular filtration rate and synthesizes Mesangial matrix
4
. 
GLOMERULAR BASEMENT MEMBRANE 
The glomerular basement membrane consists of two thin layers the 
lamina rara externa and the lamina rara interna and a dense layer the lamina 
densa. Basement membrane composed of type IV collagen. Mutation of the 
α3, α4, and α5 chains causes Alport’s syndrome. Podocalyxin present in the 
glomerular basement membrane gives its negative charge. Presence of 
anionic site in the basement membrane is demonstrated by Caulfield and 
Farquhar with the use of lysozyme. These anionic sites in the basement 
membrane are made up of glycosaminoglycans such as heparan sulfate
4
. 
JUXTAGLOMERULAR APPARATUS 
Juxtaglomerular apparatus is situated where the afferent and efferent 
arterioles meet the distal convoluted tubule. It is named because of its 
proximity to the glomerulus. JG apparatus controls function of each kidney. 
Components of the juxtaglomerular apparatus are macula densa, 
juxtaglomerular cells and extra glomerular mesangium. Macula densa is 
formed by cells of the distal convoluted tubule. Macula densa senses the 
sodium chloride concentration in the tubular fluid and secretes the locally 
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acting vasoactive substance, there by controls the GFR by changing 
efferent arteriole diameter as a part of tubuloglomerular feedback
4
. 
JUXTAGLOMERULAR GRANULAR CELLS 
Juxtaglomerular granular cells are present in the walls of the arteriole 
and extra glomerular mesangial region. They are having characteristics of 
both smooth muscle cells and epithelial cells. These cells contain renin and 
its precursor granules. 
EXTRA GLOMERULAR MESANGIAL CELLS 
Also known as lacis cells or the cells of goormaghtigh situated 
between the afferent arteriole and macula densa. Functions of the cells are 
not clearly known. It may be associated with secretion of erythropoietin. 
PROXIMAL TUBULE 
Proximal tubule is a portion of the nephron which extends from the 
Bowman’s capsule and extends up to loop of henle. It consists of proximal 
convoluted portion knows as pars convoluta and distal straight portion 
known as pars recta. Pars convoluta entirely situated in the cortex. It 
maintains the PH of the filtrate absorbs the most of the filtered components 
and secretes the creatinine and organic acids
6
. Approximately two-third of 
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the filtered water, 100% of the glucose and amino acids are absorbed from 
the proximal convoluted tubule. 
LOOP OF HENLE 
It is a U shaped portion of nephron situated in between the proximal 
and distal convoluted tubule. Most important function of the loop of henle 
is to provide high osmotic gradient inside the medulla by counter current 
system. With the help of ion channels it creates high concentration in the 
medulla, so water is absorbed from the filtrate according to osmotic 
gradient. 
DISTAL CONVOLUTED TUBULE 
It is situated between the ascending limb of loop of henle and 
collecting duct of the renal tubule. It maintains the PH, regulates electrolyte 
balance. Vasopressin acts through the receptors situated in the collecting 
duct and facilitates water reabsorption. Na+/cl- channels present in the 
distal convoluted tubules are thiazide sensitive. By inhibiting these 
channels, thiazide causes luminal Na+ gradient and also diuresis
6
. 
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FUNCTIONS OF THE KIDNEY 
A. Maintain water homeostasis. 
B. By producing erythropoietin, active form of vitamin D and renin acts      
as a endocrine organ 
C. Regulation of acid base balance. 
D. Elimination of metabolic waste products. 
E. Excretion of toxic substances from the body. 
F. Blood pressure maintenance 
G. Catabolism of small peptide hormones 
 
ACUTE KIDNEY INJURY 
Acute kidney injury is divided into three types based on aetiology. They are  
1) Pre-renal 
2) Intrinsic AKI 
3) Post renal or obstructive 
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PRE RENAL AKI 
CAUSES 
DECREASED INTRAVASCULAR VOLUME 
 
 Blood loss in trauma, operations, upper gastrointestinal bleeding and 
PPH 
 Gastrointestinal fluid loss due to vomiting, diarrhoea, nasogastric 
aspiration 
 Renal loss- osmotic diuresis, diuretics 
 Insensible water loss due to fever and burns 
 Fluid loss into body cavities in pancreatitis and hypo albuminemic 
conditions 
DECREASED STROKE VOLUME 
 Myocardial infarction 
 Dilated cardiomyopathy 
 Valvular heart disease 
 Pericarditis 
 Antihypertensive drugs 
 Pulmonary embolism 
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DRUGS 
 ACE inhibitors in bilateral renal artery stenosis.  
 Usage of NSAIDS in hypovolemic state. 
PRE RENAL ACUTE KIDNEY INJURY 
 It is the most common form of acute renal failure seen in clinical 
practice. Due to decreased blood supply, kidneys adopt themselves to 
maintain the intravascular volume. Kidney parenchyma is not affected by 
this form of renal failure. If adequate blood flow to kidneys is restored, 
GFR will become normalized. If prerenal form persists for sometime these 
patients may develop some form of acute tubular necrosis, then prerenal 
and intrinsic renal injury may overlap. 
This form of AKI is seen in conditions such as hypovolemia, 
systemic vasodilatation such as in anaphylaxis, low cardiac output states 
and in intrarenal vasoconstriction. Due to hypovolemia there is decrease in 
effective mean circulatory pressure, which results in activation of 
baroreceptors that leads to activation of RAAS, sympathetic system and 
release of ADH from posterior pituitary
7
. 
Activation these systems results in release of nor-epinephrine, 
angiotensin II and ADH which in turn causes vasoconstriction of musculo 
skeletal system, splanchnic circulation, decreases the sweat formation, 
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decreases the water excretion and increases the thirst in order to maintain 
adequate blood supply to vital organs such as brain and heart. In very early 
stages of hypovolemia there is autoregulation by prostaglandin and nitric 
oxide by which kidneys preserve GFR
7
. 
Normal GFR is maintained with wide range of blood pressure by 
varying resistance between the afferent and efferent arterioles, which 
controls the glomerular plasma flow. Both kidneys receive approximately 
20% of the cardiac output
7
. In hypovolemic states there is a decreased 
blood flow to kidneys, but blood flow to brain and heart is maintained as a 
part of autoregulation. In early phases of hypovolemia, glomerular filtration 
pressure is maintained by constriction of efferent arteriole by angiotensin 
II. 
In low perfusion states, dilatation of afferent arteriole occurs to 
maintain adequate blood flow to the glomerulus. There is increased renal 
prostaglandin synthesis occurring in hypovolemic states which causes 
vasodilatation of afferent arteriole. In low perfusion states, there is 
activation of tubuloglomerular feedback system because of decreased 
solute load in the distal tubule. 
Non-steroidal anti-inflammatory drugs block intrarenal prostaglandin 
synthesis, so that afferent arteriole vasodilatation in low perfusion states is 
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blocked. By blocking angiotensin II, ACE inhibitors block the efferent 
arteriolar constriction in response to decreased glomerular filtration 
pressure. So autoregulation in renal circulation is severely compromised. 
Thus both ACE inhibitors and NSAIDs used in combination increases the 
risk of AKI. It is advisable not to use both these drugs in combination
8
. 
 
 
 
              Fig-2 Normal Renal perfusion pressure
8 
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Fig-3 Renal auto regulation 
If renal perfusion is decreases, vasodilatory prostaglandins dilates the 
afferent arterioles and angiotensin constricts the efferent arteriole, so 
glomerular perfusion pressure and glomerular filtration rate maintained 
Fig-4 In the presence of NSAIDs this afferent arteriole vasodilatation 
by prostaglandins is affected, so there is decreased perfusion pressure 
19 
 
 
 
 
In cirrhosis, due to splanchnic vasodilatation there is decrease in 
effective circulatory volume. So there is systemic vasoconstriction like that 
is seen in hypovolemic state. Triggering factors for AKI in cirrhotic 
patients are sepsis and diuretic over usage. Type I is severe form of AKI 
seen in cirrhosis, which is very difficult to manage and fails to recover even 
after maintenance of adequate intravascular volume. Type II is less severe 
form seen in cirrhosis with refractory ascites. The treatment of choice of 
both types of hepatorenal syndrome is liver transplantation
9
. 
 
Fig-5 If ACE inhibitors given for patients with decreased perfusion 
pressure, there is no vasoconstriction of efferent arteriole, thereby 
decreases glomerular filtration rate
8
. 
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INTRINSIC AKI 
Most of the cases of the intrinsic AKI are due to progression of pre 
renal azotemia to acute tubular necrosis. This is also seen in sepsis, 
ischemia and nephrotoxic agents
9
. Basic pathophysiological mechanism in 
this type of AKI is inflammation and apoptosis. 
NEPHROTOXIN ASOCIATED AKI 
Because of relatively high percentage of blood supply, nephrotoxins 
reach kidney in high concentrations. Mostly nephrotoxins affect the renal 
tubule and epithelium but any part of the kidney can be affected by 
nephrotoxic substances. Hypoalbuminemia is associated with increased risk 
of AKI because there is increased fraction of unbound drug or 
nephrotoxins. 
SEPSIS ASOCIATED AKI 
More than half of the patients admitted with sepsis develop AKI 
even in the absence of hypotension. But some patients may also have 
associated hypotension. Renal tubular injury occurs in sepsis which leads to 
cellular debris and tubular casts. Systemic inflammatory state and 
interstitial edema also contribute to AKI. In sepsis there is an increased 
cytokine production, which leads to systemic vasodilatation and results in 
decreased renal perfusion and GFR
9
. 
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ISCHEMIA ASSOCIATED AKI 
As kidneys receive 20% of the cardiac output it is most susceptible 
to ischemia. Renal medulla is very much metabolically active, so it is 
susceptible to hypoxia mediated AKI
10
. Ischemia alone is not enough to 
cause AKI. When it is associated with chronic renal failure, septicemia, 
concurrent usage of nephrotoxic drugs, burns or pancreatitis it can lead on 
to AKI. 
POST OPERATIVE AKI 
This is a type of AKI seen after major surgeries with significant 
amount of blood loss during the procedure. Most common surgical 
procedures associated with AKI are vascular surgery, abdominal surgery, 
and cardio pulmonary bypass surgery. Risk of developing AKI is increased 
when there is a history of previous renal failure, elderly patients and during 
emergency procedure. Contrast agents used during diagnostic procedures 
are also associated with increased risk of AKI during post-operative 
period
10
. Prolonged duration of surgery and embolism during vascular 
surgery are all associated with increased risk of AKI. 
BURNS AND PANCREATITIS 
In pancreatitis there is accumulation of large amount of fluid in third 
space, which lead on to low perfusion to kidney. And as there is activation 
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of inflammation, it also causes AKI. If large volume of fluid accumulates 
in the peritoneal space, there is increased intra-abdominal pressure which 
causes compression of renal vein and AKI
10
. In burns, there is large amount 
of plasma leakage through exposed skin, thereby increasing risk of AKI. 
CONTRAST AGENTS  
Iodinated contrast agents used in CT angiogram and coronary 
angiogram are associated with increased risk of AKI. It is very unusual in 
patients with adequate hydration and normal GFR. Risk increases with 
diabetes and hypovolemic states. It is characterized by elevation of serum 
creatinine to more than 1.5mg/dl within 24 to 48 hours after contrast 
exposure
11
. Peak reaches after 3 to 5 days and return to normal in 1 week. 
Very rarely patients may develop severe renal failure; in those cases 
dialysis may be needed. Mostly patients will not develop acute tubular 
necrosis. This type of AKI develops due to direct toxicity of contrast 
agents; reactive oxygen species mediated injury or decreased blood supply 
to renal medulla due to occlusion of renal micro vessels
11
. Even high dose 
of gadolinium, oral sodium phosphate can cause renal injury. 
ANTIBIOTICS 
Antibiotics can cause AKI. Amphotericin B causes reflex 
vasoconstriction of renal vessels and direct damage to the tubules. Toxicity 
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is duration and time dependent. Amphotericin binds with tubular 
membrane and causes pores in it, through which cellular contents leak. 
Toxicity of this drug is characterized by low urinary concentration, 
increased frequency of micturition, and metabolic acidosis. 
Aminoglycoside antibiotics such as gentamycin and streptomycin cause 
renal injury by direct tubular toxicity. It is the most common pathological 
mechanism behind the renal failure in aminoglycoside use
12
. It causes non 
oliguric renal failure. Urine is typically hypo-osmolar in concentration. It 
may cause injury in normal plasma concentration also. Measurable quantity 
of drug reaches the proximal convoluted tubule cells and causes damage to 
them. It is associated with low serum magnesium concentration. 
Vancomycin in high doses can cause renal injury. Acyclovir when 
used in dehydrated states precipitates in renal tubules and causes 
obstructive nephropathy. Renal tubular toxicity is also caused by cidofovir, 
pentamidine and foscarnet. Other drugs causing tubular damage are 
cisplatin and carboplatin which can be prevented by adequate hydration. 
Penicillin, cephalosporin, quinolones and rifampin cause interstitial 
nephritis. Cyclophosphamide and ifosfamide cause tubular damage and 
hemorrhagic cystitis. Gemcitabine, bevacizumab and mitomycin-c cause 
thrombotic micro angiopathy manifested by proteinuria and hypertension. 
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TOXIN INGESTION 
Ethylene glycol causes direct tubule damage; it is used as automobile 
anti-freeze. Melanamine present in the certain food stuffs can cause renal 
stone and acute kidney injury. Consumption of Chinese herbs containing 
aristocholic acid causes Chinese herbs nephropathy and progressive renal 
fibrosis. Unidentified environmental toxins can cause chronic tubular 
interstitial nephritis. 
ENDOGENOUS TOXIN 
Whenever there is hemolysis or rhabdomyolysis, hemoglobin or 
myoglobin is released into systemic circulation respectively. These 
pigments deposit in the renal tubule and can cause pigment nephropathy. 
This can be prevented by alkalization of urine. Tumor lysis syndrome is 
seen in conditions like leukemia and lymphoma. After starting 
chemotherapy large amount of uric acid is released into circulation, which 
precipitates in the renal tubules causing renal injury. In multiple myeloma 
there is deposition of light chains in the renal tubules. These light chains 
can cause myeloma kidney. By causing vasoconstriction and volume 
depletion, hypercalcemia can cause renal tubular injury. 
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Differentiating prerenal and ATN by urine analysis 
 Pre-renal ATN 
Urine Osmolarity 
(mOsm/L) 
>500  <350 
  
Urine Na (mmol/L) 
 
<20 
 
>40 
 
Urine/plasma creatinine 
>40 <20 
Urine/plasma urea >8 
 
<3 
 
Fractional Na excretion 
(%) 
<1 >2 
POST RENAL AKI 
Post renal acute kidney injury occurs due to any obstruction from the 
renal pelvis to urethra. In post renal AKI there is increased pressure in the 
tract which interferes with glomerular filtration. Even if urine output is 
normal it does not rule out the urinary tract obstruction. Benign prostatic 
hypertrophy, prostate cancer, anti-cholinergic drugs, neurogenic bladder, 
blocked Foley’s catheter, and urethral stricture are the most common 
causes of post renal AKI. USG abdomen and pelvis, CT abdomen and MRI 
abdomen are necessary to localize the site of obstruction. 
COMPLICATIONS OF AKI 
Excretion of sodium and potassium is decreased in AKI leading to 
volume overload, electrolyte imbalance such as hyperkalemia and 
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hyponatremia. Other metabolic abnormalities are hyperphosphatemia, 
hypermagnesemia and hypocalcemia. Oliguric patients have elevated 
creatinine and urea and these patients are at increased risk of 
complications. Acidification of urine is impaired in AKI leading to 
metabolic acidosis. Impaired excretion of nitrogenous substances cause 
uremic syndrome. 
The increased intravascular volume seen in most of the AKI patients 
is due to impaired salt and water excretion. Clinical features of the AKI are 
elevated jugular venous pulse, crepitations in the lung bases, pleural 
effusion, ascites, facial puffiness, mild elevation of BP, recent increase in 
body weight and pulmonary edema. If blood pressure is very high we have 
to think of some other co-existing problems. Hypotonic solutions should be 
avoided in AKI patients because it may worsen hyponatremia
13
. 
The most important complication of AKI is hyperkalemia, as it is 
directly associated with increased mortality. Mostly this is seen in oliguric 
renal failure patients. Co-existing metabolic acidosis worsens the 
hyperkalemia, which causes efflux of potassium from the cells. If serum K
+ 
is less than 6Meq/L, it usually not associated with any symptoms. Severe 
hyperkalemia is mostly seen in conditions associated with massive 
destruction of cells like rhabdomyolysis, hemolysis and tumor lysis 
syndrome. Elevated serum potassium is associated with certain ECG 
27 
 
features such as reduced amplitude of P waves, PR interval prolongation, 
tall and tented T waves and sine wave pattern. It may result in bradycardia, 
complete heart block, ventricular tachycardia, ventricular fibrillation and 
asystole (diastolic arrest). Neuromuscular abnormalities associated with 
hyperkalemia are diminished deep tendon reflex, respiratory muscle 
weakness and weakness of limbs
13, 14
. Hypokalemia is very rarely seen in 
AKI except in non-oliguric ATN caused by drugs. 
In AKI there is increased production of sulfuric acid and phosphoric 
acid, due to increased catabolism of proteins. These acids are usually 
excreted by kidneys. Impaired excretion of these acids leads to metabolic 
acidosis in AKI. Very severe acidosis can be seen if there is associated 
diabetic ketoacidosis, lactic acidosis and sepsis. Very rarely metabolic 
alkalosis may present in AKI due to over correction of acidosis or loss of 
hydrochloric acid due to severe vomiting. 
Mild elevation of serum uric acid level may be seen in AKI, usually 
it is asymptomatic. If uric acid levels are high, urate nephropathy should be 
thought of.  Over production of urate is differentiated from impaired 
excretion by measuring urinary urate and creatinine ratio. If the ratio is <1 
it is due to impaired excretion and if the ratio is >1 it is due to 
overproduction. 
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AKI is associated with mild hyperphosphatemia. If serum phosphate 
level is very high, it may be due to massive destruction of cells, which is 
seen in hemolysis, tumor lysis syndrome and rhabdomyolysis. When 
calcium and phosphorus product is more than 70, it is associated with 
deposition of calcium phosphate in tissues. Asymptomatic hypocalcemia 
seen in AKI; it is due to the effect of acidosis on neuromuscular hyper 
excitability. It becomes symptomatic when acidosis is corrected with 
bicarbonate. Clinical manifestations of hypocalcemia are cramps, perioral 
numbness, tetany and convulsions. ECG features of hypocalcemia are QT 
prolongation and T wave changes
14
. Trousseau and chvostek signs 
positivity indicates latent tetany. A mild asymptomatic elevation of serum 
magnesium is also seen in AKI. 
Hemodilution due to volume overload, impaired erythrocyte 
survival, decreased erythropoietin secretion, lysis of RBC all lead to 
anemia in AKI. Bleeding time is increased due to mild thrombocytopenia. 
Leukocytosis may present in AKI. Co-existent infection increases the 
mortality in AKI. 
Cardiac complications seen in AKI are arrhythmia and pulmonary 
embolism. Myocardial contractility is decreased in AKI, due to metabolic 
acidosis, fluid overload, hyperkalemia and other electrolyte disturbances
15
. 
Mostly pulmonary embolism is due to prolonged immobilization. Upper 
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gastrointestinal bleeding can occur due to stress ulcer. Metabolic 
encephalopathy, uremic encephalopathy and thrombotic microangiopathy 
are causes of altered mental status seen in acute renal failure.  
Malnutrition is one of the most dreaded complications of AKI. 
Various factors contributing to this are massive myolysis, decreased food 
intake, loss of nutrient during dialysis and decreased synthesis of muscle 
protein
16
. Patients with AKI may also have pericarditis and tamponade. 
GIT complications are nausea, vomiting, anorexia and paralytic ileus. 
Neurological manifestations of AKI are lethargy, psychosis, 
myoclonus, confusion, asterixis and coma. Uremic manifestations of AKI 
are due to aromatic amines, guanidine compounds and urea. 
Diuretic over usage during recovery may cause volume depletion and 
further aggravates the kidney injury. If fluid intake is not adequate in this 
period, hypernatremia can occur. If urine output is more than 400 ml/day it 
is called non-oliguric renal failure and less than 400ml/day it is called 
oliguric renal failure. If urine output is less than 100ml/day it is called as 
anuria
17
. Less urine output indicates more severe renal injury. 
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COURSE OF AKI 
There are 3 phases in AKI (1) Initiation phase  
         (2) Maintenance phase 
         (3) Recovery phase 
Initiation phase is a reversible period extending from exposure to the 
toxin or initiating event to the onset of kidney injury but not fully 
established. This is followed by maintenance period. In this phase the 
kidney parenchyma is fully injured and glomerular filtration lowers to the 
approximately around 10ml/min. In this phase patient is mostly oliguric. 
This phase will last for up to 2 weeks
17
. Very rarely this may be prolonged 
for months together. During Recovery phase there is increase in urine 
output and returning of biochemical abnormalities to base line.  
DIAGNOSIS 
While evaluating the patient with elevated renal parameters it is 
essential to differentiate AKI from CKD. Hypertension, anemia, 
hyperparathyroidism, evidence of renal osteodystrophy and bilateral 
contracted kidneys in ultra-sonogram are suggestive of chronic kidney 
disease. Anemia is also present in long standing acute kidney injury. 
Normal or increased sized kidneys are seen in CKD with polycystic kidney 
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disease, diabetes, amyloidosis and HIV nephropathy. Once diagnosis of 
AKI is confirmed, we have to differentiate it into prerenal, intrinsic and 
post renal AKI. For this detailed history and clinical examination should be 
done. 
INVESTIGATION 
 Urine analysis:  albumin, sugar, deposits, casts, specific gravity, 
eosinophil. 
 Complete hemogram with peripheral smear 
 Blood: serum creatinine, blood urea, serum electrolytes. 
 Autoantibody: ANA, ANCA, Anti glomerular basement membrane. 
 ASO titre, anti-DNAse titre. 
 Serum electrophoresis. 
 Ultra sonogram of abdomen. 
 CT abdomen &Renal biopsy 
MANAGEMENT OF AKI 
Prime important in the management of AKI is the treatment of the 
underlying precipitating event. Management consists of monitoring of vital 
parameters, avoiding and stopping nephrotoxic drugs, fluid and electrolyte 
correction and adjustment of dose of drugs according to glomerular 
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filtration rate. Usually kidneys recover from the injury with this supportive 
care. Rarely some patients require dialysis for some period. 
Renal replacement therapy in the form of dialysis is also a supportive 
therapy. It doesn’t improve the kidney recovery. 
Indications for renal replacement therapy are 
1) Hyperkalaemia 
2) Refractory acidosis 
3) Refractory volume overload 
4) Uremic symptoms. 
OUTCOME 
Mortality is very high in intrinsic AKI as compared with other two 
forms. Mortality rate varies depending upon the etiology. 30% in toxin 
induced AKI, 60 to 70% in sepsis induced and 15% in gynecological 
causes
18
.  
Factors associated with poor prognosis are  
1) Serum creatinine more than 3 mg/dl 
2) Male patients 
3) Oliguric AKI 
4) Old age 
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CHRONIC KIDNEY DISEASE 
Chronic kidney disease is emerging as a major health related issue 
worldwide. Developing countries like India are not able to manage these 
patients because of increasing cost. Incidence and prevalence of CKD is 
increasing because of the increased survival and improved quality of 
treatment. The term chronic renal failure corresponds to CKD stages 3-5, 
applies to the processes of irreversible reduction in nephron number. End 
stage renal disease represents the stage in which survival is not possible, 
unless the uremic toxins are removed by appropriate renal replacement 
therapy. This syndrome is caused by accumulation of toxins, fluids and 
electrolytes that are normally excreted by kidneys. 
Most common causes of ESRD are diabetes, hypertension, 
polycystic kidney disease and glomerulonephritis. These together 
contribute to more than 90% of the cases of ESRD. Other causes for CKD 
include interstitial nephritis and HIV
19
. Nephropathy due to systemic 
hypertension is the most common cause for end stage renal disease in 
elderly patients. Nephrosclerosis from vascular disease process correlates 
with coronary and cerebrovascular disease. 
Because of decreased mortality related to atherosclerotic coronary 
complications, greater segment of the population manifests the renal 
counter part of generalized vascular disease. In early stages of CKD, 
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patients usually will die of cardiovascular and cerebrovascular 
complications before they progress to ESRD. Renal disease progression 
varies from person to person, so this leads to genetic research to identify 
the inheritable component. A number of genetic loci that are contributing to 
the development of kidney disease have been identified. 
Chronic kidney disease is divided into five stages based on the 
estimated glomerular filtration rate (GFR). In stage 1and stage 2 the GFR is 
normal or near normal, so based on the structural or functional defect these 
two are differentiated. 
DEFINITION OF CHRONIC KIDNEY DISEASE 
The National Kidney Foundation [Kidney Disease Outcomes Quality 
Initiative (KDOQI)] has proposed a definition and classification scheme of 
CKD. The National kidney foundation guidelines define CKD on the basis 
of kidney damage and/or reduced renal function. Kidney damage may be 
confirmed through a variety of methods including renal imaging, 
abnormalities in the serum or urine biochemistry and histological evidence. 
Albuminuria is the most frequent early indicator of kidney damage. 
CRITERIA: 
1. Structural or functional abnormality of the kidney for more than 
3 months, with or without decreased urine output, manifested by 
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 Pathological abnormalities 
 Markers of kidney damage 
i. Urinary abnormalities (proteinuria). 
ii. Blood biochemical abnormalities. 
iii. Imaging abnormalities. 
2. GFR <60 ml/min/1.73m2 BSA for >3 months with or without 
kidney damage. 
 
RISK FACTORS FOR CKD 
Established risk factors: 
 Age 
 Gender 
 Race 
 Diabetes mellitus 
 High blood pressure 
 Proteinuria 
 Atherosclerosis 
 Family history of kidney disease 
 Reduced nephron number at birth 
 Obesity 
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 Metabolic syndrome 
 Family history of kidney disease 
 Smoking 
 Exposure to nephrotoxins 
 Dyslipidaemia 
 Recurrent urinary tract infection 
Emerging risk factors: 
 Elevated plasma homocysteine level 
 Oxidative stress 
 Prothrombotic factors (e.g. Plasminogen activator protein) 
 Anaemia 
 
STAGES OF CHRONIC KIDNEY DISEASE 
Kidney disease outcome quality initiative (NKF-KDOQI) staging 
system: Importances of this staging are
20, 21 
1. It shifts the focus from GFR as the sole criteria for defining chronic 
kidney disease to the identification of markers of early kidney 
damage including proteinuria and abnormal urinary sediment. 
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2. The concept of CKD with normal glomerular filtration rate, but with 
markers of kidney damage like persistent proteinuria is providing 
guidelines for optimal treatment at early stage. 
This system of staging helps us to plan for further treatment and also 
helps in predicting the outcomes. Thus there is a need for early detection 
and treatment. 
 
 
STAGE 
 
DESCRIPTION 
GFR 
(ml/min/1.73m
2
) 
 
ACTION 
1 Kidney damage with 
normal GFR 
>90 Diagnosis and treatment of 
comorbid condition, slow 
progression, CVD risk reduction. 
2 Kidney damage with 
mild reduction of GFR 
60-89 Estimating progression. 
3 Moderate reduction of 
GFR 
30-59 Evaluate and treat complication. 
4 Severe reduction of 
GFR 
15-29 Preparation of renal replacement 
therapy. 
5 ESRD <15 Renal replacement therapy 
 
 
 
 
38 
 
CAUSES OF CHRONIC KIDNEY DISEASE 
1. Diabetic glomerulosclerosis 
2. Hypertensive Nephrosclerosis. 
3. Glomerular diseases: 
 Glomerulonephritis 
 Amyloidosis, light chain disease. 
 Systemic lupus erythematosus. 
 Wegener’s granulomatosis. 
4. Tubulointerstitial diseases: 
 Reflux nephropathy (chronic pyelonephritis). 
 Analgesic nephropathy. 
 Obstructive nephropathy (stones, benign prostatic 
hypertrophy). 
 Myeloma kidney. 
5. Vascular diseases: 
 Scleroderma. 
 Vasculitis. 
 Reno vascular renal failure 
 Atheroembolic renal disease. 
6. Cystic diseases: 
 ADPKD. 
 Medullary cystic kidney disease. 
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There is a difference between the etiologies of CKD in India when 
compared to world-wide incidence. For example, in North America the 
commonest cause for CKD is diabetic nephropathy and the next being 
hypertensive glomerulosclerosis. But in India although large scale data are 
unavailable, glomerulonephritis is the leading cause for CKD over diabetes 
and hypertension. 
In most of the patients while diagnosing CKD, there is an associated 
systemic hypertension. If there is no identifiable cause for glomerular 
disease or tubular pathology, the etiology is often attributed to systemic 
hypertension. But such patients without identifiable etiological factors are 
considered in the following categories. 
1) Patient with silent primary glomerulopathy, like focal segmental 
glomerulosclerosis without overt nephrotic or nephritic 
manifestations of glomerular disease. 
2) Patients with chronic renal ischemia attributed to systemic 
vascular disease involving large and small vessels, cardiac and 
cerebral pathology. Here systemic hypertension is considered to 
be the renal correlate of systemic vascular disease. 
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PATHOPHYSIOLOGY OF CKD 
It involves two broad sets of mechanisms 
1. According to the mechanisms that are specific to the underlying etiology 
that initiate the kidney damage. (e.g. Genetic abnormalities in the 
development of kidney, deposition of immune complexes and 
inflammatory mediators as in glomerulonephritis or exposure of toxins in 
diseases of renal tubules and interstitium). 
2. Progressive mechanisms involving hyper filtration and hypertrophy of 
the remaining viable nephrons that are common consequence following 
reduction of renal mass, irrespective of the underlying etiology. These 
adaptive responses to reduction in nephron number are mediated by a 
number of vasoactive hormones, cytokines and growth factors. Renin 
aldosterone system is responsible for hyperfiltration and subsequent 
hypertrophy and sclerosis. 
The increased intra-renal renin activity contributes to both initial 
inciting event and also to the progressive mechanisms, finally leading on to 
the glomerular sclerosis, renal failure and uremic syndrome. 
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PATHOPHYSIOLOGY OF UREMIC SYNDROME 
The pathophysiology behind the uremic syndrome can be classified into 
1) Due to the accumulation of toxins that are normally excreted via 
the kidneys. 
2) Due to impairment of fluid and electrolyte homeostasis and 
hormone regulation. 
3) Progressive systemic inflammation and its consequences 
Various excretory products accumulating in renal dysfunction are 
nitrogenous and non-nitrogenous products such as urates, products of 
nucleic acid metabolism, phenols, guanido compounds, hippurates, indoles, 
middle molecules, etc. Accumulation of these waste products leads to 
anemia, metabolic abnormalities of carbohydrate, protein and fat and 
malnutrition resulting in a clinical syndrome which is characteristic feature 
of end stage renal disease. There is alteration of metabolism of many 
hormones like insulin, glucagon, PTH and vitamin-D due to increased renal 
excretion, decreased degradation and abnormal regulation. 
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SUMMARY OF PATHOPHYSIOLOGY OF CKD 
Vasoactive molecules, cytokines, growth factors, renin angiotensin axis 
 
         Glomerular hyperperfusion, hypertension, hyperfiltration 
 
                       Glomerular hypertrophy and sclerosis 
 
                               Reduced renal mass and function. 
 
 
Fig-6 Due to chronic nephron loss some of the viable nephrons 
become hypertrophied and enlarges
8, 9
.  
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FACTORS INFLUENCING RENAL PROGRESSION 
There are some factors affecting the progression of renal disease. 
The rate of disease progression can be modified by modifying these risk 
factors. It includes: 
1. Hypertension. 
2. Diabetes. 
3. Hyperlipidaemia. 
4. Abnormal calcium-phosphorus homoeostasis. 
5. Genetic factors. 
6. Cigarette smoking. 
7. Renin-angiotensin system activation. 
8. Excessive dietary protein. 
9. Obesity. 
10. Prematurity/low birth weight. 
CLINICAL PRESENATION 
Most of the patients are asymptomatic in the early stages of chronic 
kidney disease; mostly they do not come to medical attention until most of 
the kidney function is compromised by the disease process. Any organ 
system can be affected by the kidney disease. Anemia, proteinuria and 
hypertension are the most common manifestations present in the most of 
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the patients. Clinical presentation depends upon the systems involved. 
These include: 
1) Disorders of fluid, electrolyte and acid-base homeostasis 
2) Disorders of calcium and phosphate metabolism 
3) Disorders of cardiovascular system 
4) Haematological abnormalities 
5) Neuro-muscular abnormalities 
6) Gastro-intestinal and nutritional abnormalities 
7) Endocrine-metabolic disturbances 
8) Dermatological abnormalities 
ELECTROLYTE AND ACID-BASE DISORDERS 
SODIUM AND WATER HOMEOSTASIS 
In patients with stable CKD, there is a clinically insignificant 
increase in total body water and sodium content. In most of the CKD 
patients daily intake of sodium exceeds its urinary excretion leading to 
sodium retention and extracellular volume expansion. This is also one of 
the contributing factors for development of hypertension. Hyponatremia is 
very rarely seen in CKD patients; even if present it will respond to water 
restriction. 
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POTASSIUM   HOMEOSTASIS 
Hyperkalemia in CKD may be due to the following mechanisms:   
     A. Increased dietary potassium intake  
                        B. Protein catabolism 
                        C. Hemolysis 
                        D. Transfusion of stored blood 
                        E. Metabolic acidosis.  
Hypokalemia is not common in CKD. It may occur in markedly reduced 
dietary intake, excessive diuretic therapy and gastro intestinal losses. 
Metabolic acidosis: 
It is a common metabolic abnormality seen in ESRD patients. The 
combination of hyperchloremic metabolic acidosis and hyperkalemia is 
often present. In early stages of CKD non anionic gap metabolic acidosis is 
present, but in later stages anionic gap metabolic acidosis ensues. Renal 
ammonia production is increased during treatment of hyperkalemia and 
also renal production of bicarbonate is increased, thereby improving the 
metabolic acidosis. 
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BONE MANIFESTATIONS OF CKD 
The two main types of bone disease in chronic kidney disease are 
adynamic bone disease and osteitis fibrosa. Low bone turnover leads to 
adynamic bone disease and osteomalacia. It is most commonly seen in 
diabetes and elderly individuals. Adynamic bone disease is characterized 
by decreased mineralization and bone volume resulting in fracture and 
pain. It is also associated with vascular and cardiac calcification. 
Osteomalacia is caused by metabolic acidosis, vitamin D deficiency and 
aluminium deposition that are present in the alkali. Secondary 
hyperparathyroidism that is seen in CKD is the main reason for high bone 
turn over. This high bone turnover causes osteitis fibrosa cystica. This is 
characterized by fragility, brown tumors and compression syndromes. 
Renal osteodystrophy results from secondary hyperparathyroidism. 
 
GASTROINTESTINAL MANIFESTATIONS 
Gastritis, peptic ulcer disease and mucosal ulcerations can occur in 
any part of GI tract resulting in abdominal pain, nausea, vomiting and GI 
bleeding. These patients are prone for constipation which can be worsened 
by calcium and iron supplements. Protein energy malnutrition is common 
in advanced stages of CKD. It is due to low protein diet and increased 
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catabolism of proteins. Metabolic acidosis and activation of inflammatory 
cytokines promote protein catabolism. Every patient should be assessed for 
malnutrition from stage 3 of CKD. 
NEUROMUSCULAR MANIFESTATIONS 
Central nervous system, peripheral and autonomic neuropathy as 
well as abnormalities in the muscle structure and function are recognized 
complications of CKD. Nitrogenous metabolites and middle molecules that 
are accumulating in CKD contribute to the pathophysiology of 
neuromuscular abnormalities. In the early stages of CKD, patients present 
with disturbances in the memory, sleep and concentration. Neuromuscular 
irritability including hiccups, cramps and fasciculation or twitching of 
muscles are seen in later stages. Asterixis, myoclonus, seizures and coma 
may occur in advanced untreated cases due to uremic encephalopathy
21, 22
. 
Presence of peripheral neuropathy without any other cause is one of 
the indications for renal replacement therapy; it usually occurs from stage 4 
of CKD. Sensory nerves more involved than the motor. It presents as distal 
symmetric polyneuropathy. 
ENDOCRINE & METABOLIC MANIFESTATIONS 
Metabolism of glucose is impaired in chronic kidney disease. As 
insulin excretion by the kidneys is impaired, there is elevation of plasma 
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insulin level. As hypoglycemic episodes are more common in CKD, doses 
of insulin and oral hypoglycemic agents should be reduced. In women with 
CKD, estrogen levels are low. Menstrual abnormalities and infertility are 
common. Pregnancy may hasten the progression of the disease. 
Spontaneous abortions and miscarriages are common. Sexual dysfunction 
and oligospermia are common in men with CKD. 
DERMATOLOGIC MANIFESTATIONS 
Most common and devastating complication of chronic kidney 
disease is pruritus. Hyperpigmentation of the skin is also one of the 
dermatologic complications of the CKD. Progressive subcutaneous 
induration of arms and legs occurs in CKD patient after exposing them to 
gadolinium contrast. It is called nephrogenic fibrosing dermopathy. 
HYPERTENSION AND CHRONIC KIDNEY DISEASE 
Hypertension is almost present in all the CKD patients and often the 
first manifestation of the disease. More than 90% of patients with CKD 
experience hypertension during the course of the disease. Uncontrolled 
hypertension accelerates the rate of progression of the renal disease. 
Clinical trials and epidemiologic studies indicate that hypertension is a 
major risk factor for CKD. Hypertension contributes to the development of 
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cardiovascular disease, the leading cause of morbidity and mortality in 
CKD patients. 
Hypertension in CKD patients is mainly the result of an increased 
extracellular volume and a decreased excretion of sodium. Another 
mechanism for hypertension in CKD patients is the activation of renin –
angiotensin – aldosterone system (RAAS) and the sympathetic nervous 
system. Vasoconstrictive action of the angiotensin and salt retaining 
property of the aldosterone are responsible for hypertension seen in CKD 
patients. Serum uric acid level is also elevated in CKD patients thus 
contributing to vascular damage and hypertension. 
Multiple Risk Factor Trial (MRFIT) has established a strong 
correlation between hypertension and rate of decrease in kidney function. 
National Health and Nutrition Evaluation Survey (NHANES) III suggests 
that adequate control of BP is achieved in only eleven percent of the 
patients. Causes for uncontrolled hypertension in chronic kidney disease 
patients are  
1) Age more than 60 years 
2) Presence of albuminuria 
3) Associated other diseases like coronary heart disease, 
cerebrovascular accident and diabetes. 
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Documentation and serial monitoring of blood pressure in every 
CKD is vital, because this strongly correlates with disease progression and 
cardiovascular event. Treatment of high BP in CKD should include 
specification of target blood pressure levels, nonpharmcologic therapy and 
specific anti-hypertensive agents for the prevention of progression of 
kidney disease and cardiovascular morbidity. Antihypertensive treatment 
reduces albuminuria and reduces its progression even in normotensive 
diabetic patients. Degree of blood pressure control appears to be an 
important factor in the rate of progression of CKD. 
Based on the kidney disease improving global outcomes (KDIGO) 
the following were practiced in the management of hypertension in CKD. 
1. In both diabetic and non-diabetic CKD patients with BP more than 140 
mm Hg systolic and 90 mm Hg diastolic should be treated with anti-
hypertensive drugs. 
 
2.  The target BP to be achieved was based on urine albumin excretion rate. 
 For patients with urine albumin excretion of less than 30mg per 24 
hours the BP should be maintained at <140mm Hg systolic and <90 
mm Hg diastolic. 
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 For patients with urine albumin excretion of more than 30 mg per 24 
hours the BP should be maintained at <130 mm Hg systolic and <80 
mm Hg diastolic. 
 
3. Angiotensin converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers (ARB) can be used to achieve the target BP. 
 
4. Individualize BP target and agents according to age, coexistent 
cardiovascular disease and other co-morbid illness and tolerance to the 
treatment. 
 
5. The combinations of ACE inhibitors with ARBs are not recommended. 
ANEMIA AND CHRONIC KIDNEY DISEASE 
Anemia is one of the most common problems in chronic kidney 
disease patients. The cause for anemia in CKD is multifactorial. Usually it 
is normochromic due to erythropoietin deficiency and other factors like 
iron deficiency also contributes a major proportion. Anemia is a 
multifactorial risk factor for the progression of CKD to end stage renal 
disease (ESRD) which reduces the quality of life and associated with 
significant morbidity and mortality.  
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Anaemia in diabetic patients has peculiar features as early onset and 
more severe in magnitude. Severity of the anaemia reflects the severity of 
the disease. Absolute level of haemoglobin that defines anaemia in CKD 
has been determined by national kidney foundation’s kidney disease 
outcome quality initiative guidelines as a level of less than 12 gm/dl for 
men, postmenopausal women and 11 gm/dl in premenopausal women. 
In general, anaemia becomes more frequent as renal function 
declines, becoming almost universal in ESRD. Studies have demonstrated 
correlation of anaemia with progression of renal failure. A randomized 
cohort study RENAAL (Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan) reports that each 1g/dl decrease in 
hemoglobin concentration from baseline is associated with an 11% increase 
in the risk of developing renal failure. Moderate to severe anaemia, 
(hematocrit less than 33%) is common only when GFR is less than 
30ml/min in women and 20ml/min in men. Erythropoietin deficiency along 
with absolute or functional deficiency of iron, accounts for nearly 90% 
cases of anaemia. Anaemia is also a risk factor for the progression of CKD. 
Several small studies indicate that treatment of anaemia may slow the 
progression of CKD. Anemia in CKD is usually normocytic normochromic 
anemia. If microcytosis is present, then iron deficiency, thalassemia and 
myelodysplasia should be considered. 
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ETILOGY OF ANEMIA IN CKD 
BASIC ETIOLOGY 
1) Erythropoietin deficiency. 
2) Iron deficiency (absolute/functional). 
3) Decreased RBC survival. 
4) Reduced dietary intake and absorption. 
5) Bleeding diathesis. 
6) Urinary loss of transferring as a part of proteinuria leading to 
impaired iron transport. 
CONTRIBUTORY FACTORS: 
a) Uremic toxins. 
b) Immunosuppressive drugs. 
c) Aluminium toxicity. 
d) Secondary hyperparathyroidism and bone marrow fibrosis. 
e) Folate and vitamin B12 deficiency. 
f) Associated HIV/HCV infections. 
g) Chronic inflammation and release of inflammatory cytokines. 
h) Haemoglobinopathy. 
i) Co-morbid conditions like hypo/hyperthyroidism, pregnancy, auto-
immune diseases. 
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Anaemia and its direct consequence, reduced oxygen delivery and 
utility may have detrimental effects in patients with CKD. Worsening of 
anaemia could potentially accelerate the progression of kidney disease. 
Anaemia has a direct effect on cardiovascular system increasing the 
morbidity and mortality in CKD patients. Anaemia plays an important role 
in the development of congestive cardiac failure and left ventricular 
hypertrophy. Reduced oxygen carrying capacity consequent to anaemia in 
CKD results in tissue hypoxia which in turn aggravating the uremic 
symptoms. It also produces a state of abnormal haemostasis. Anaemia 
plays an important role in platelet dysfunction. The phagocytic activity of 
the granulocytes may be reduced. Cell-mediated immunity is depressed 
resulting in increased incidence of infections. 
EVALUATION OF ANEMIA IN CKD 
Because the diagnosis of erythropoietin deficiency is one of the 
exclusion, the evaluation should focus on excluding the other causes of 
anaemia with an appropriate history, examination and laboratory testing. 
 Haemoglobin  
 Complete blood count  
 Red blood cell indices, 
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 Faecal blood testing and upper gastro duodenoscopy should be 
performed. 
 Iron profile including serum Ferritin and transferrin saturation should 
be done to rule out iron deficiency. 
 If microcytosis is present then thalassemia, iron deficiency and 
myelodysplasia should be considered. With macrocytosis, folic acid and 
vitamin B12 deficiency must be excluded. Echinocytes or burr cells in 
peripheral smear are characteristic of CKD. 
TREATMENT OF ANEMIA 
Based on National Kidney Foundation’s (NKF) Kidney Disease 
Outcomes Quality Initiative (KDOQI) guidelines, the target haemoglobin 
to be achieved is 12 g/dl for both men and women regardless of stage of 
CKD. Patients with haemoglobin levels less than 11 g/dl are candidates for 
treatment. In adult CKD patients with anaemia, not on iron or 
erythropoietin therapy a trial of intravenous iron therapy is suggested. 
Erythropoietin therapy is not indicated in adult CKD patients with Hb 
concentration of more than 10 g/dl. And in patients with less than 10 g/dl 
the decision to start erythropoietin therapy should be individualized based 
on the rate of fall of hemoglobin, prior response to iron therapy, transfusion 
related risks and the risk related to erythropoietin therapy. 
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CALCIUM AND PHOSPHATE METABOLISM IN CKD 
The main complication of abnormality in the calcium and 
phosphorus metabolism in CKD patients is calcium deposition in the 
vascular bed. As the kidneys play a major role in the calcium and 
phosphorous metabolism, they are essential to maintain the calcium and 
phosphorous in appropriate level. These abnormalities do not occur unless 
the GFR is reduced to 60ml/min. If the GFR reduced to 30ml/min, calcium 
and phosphorous abnormality will present in almost all patients. 
Commonly seen metabolic abnormalities include hyperphosphatemia, 
hypocalcemia and abnormal vitamin D metabolism. 
Normal serum calcium and phosphorous levels are maintained by 
1) Parathyroid hormone 
2) 1, 25 dihydroxycholecalciferol. 
These hormones act on three primary target organs: bone, kidney and 
intestine to maintain serum calcium and phosphorus. 
 Secondary hyperparathyroidism leads to metabolic abnormalities of 
calcium and phosphorous in the following ways. 
 Reduced phosphate excretion due to declining GFR and phosphate 
retention. 
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 Retained phosphate stimulates parathyroid resulting in 
hyperparathyroidism and hyperplasia of the glands. 
 Hypocalcaemia due to reduced calcitriol and phosphate retention also 
stimulates parathyroid resulting in hyperparathyroidism. 
CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER 
It is defined as a systemic disorder of mineral and bone metabolism due 
to CKD manifested by either one or a combination of the following: 
 Abnormalities of Phosphorus, calcium, PTH and vitamin D 
metabolism. 
 Abnormalities in bone turn over, mineralization, volume, growth or 
strength. 
 Vascular and other soft tissue calcification. 
CARDIO-VASCULAR EFFECTS OF CKD 
The most common cause of mortality in chronic kidney disease is due to 
cardiovascular disease. There is 30 times higher mortality in ESRD patients 
when compared to age and sex matched general population. Cardiovascular 
mortality is higher in those patients with dialysis than patients without 
dialysis. Cardiovascular events start in early stages of kidney disease, so 
most of the patients die of cardiovascular mortality before reaching ESRD. 
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So management should begin in the early stage of the disease to prevent 
cardiovascular mortality. 
The following conditions form the major part of the cardiovascular 
complications of CKD,
 
1) Cardiomyopathy 
2) Ischemic heart disease 
3) Left ventricular hypertrophy 
4) Cardiac failure 
CVS risk is increased in CKD due to the vascular calcification. Most of the 
vascular calcification in CKD is due to dystrophic calcification. Aortic 
valve is affected more commonly than mitral valve. The Valvular 
calcification and atherosclerosis cause significant stenosis of the coronary 
artery. 
PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE IN CKD 
Patients with CKD are more likely to develop cardiovascular disease 
related mortality because of accelerated atherosclerosis. In addition these 
patients present with atypical symptoms, which leads to delay in diagnosis 
and affects the outcome. Risk factors for cardiovascular disease are. 
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TRADITIONAL RISK FACTORS 
 Male gender 
 Smoker 
 Dyslipidaemias 
 Hypertension 
 Left ventricular hypertrophy 
 Diabetes mellitus 
 Older age 
 Physical inactivity 
CKD RELATED RISK FACTORS 
 Hypertension 
 Sodium retention 
 Angiotensin II 
 Generalised inflammation 
 Myocarditis, pericarditis 
 Anaemia 
 Proteinuria 
 Hypervolemia 
 Elevated calcium-phosphate product 
 Hyperphosphatemia 
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 Hyperparathyroidism 
 Genetic factors  
EMERGING RISK FACTORS 
 Insulin resistance 
 Hyper homocysteinemia 
 Lipoprotein. 
 Inflammation. 
Myocardial infarction is responsible for 30 to 50 percent of deaths in 
CKD patients. Myocardial ischemia tolerance is greatly reduced in CKD, 
even in the absence of associated atherosclerotic changes.  
85% of the patients on dialysis already have left ventricular disease. 
Microvascular disease in the coronary circulation is also more common in 
CKD patients. Intramyocardial arterial wall thickening is present in the 
absence of associated hypertension and it interferes with perfusion of 
myocardium. Besides the anticipated accelerated atherosclerosis of aorta 
and peripheral arteries, calcification of the arterial media especially in the 
aorta lead on to aortic stiffness which is an independent risk factor for 
cardiovascular mortality. CKD is an inflammatory state which causes 
elevation of acute phase reactants like CRP and other inflammatory 
cytokines. In the presence of inflammation, vascular occlusive disease 
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process is accelerated, that too in the milieu of hyperphosphatemia leads to 
vascular calcification. So in every CKD patient we have to evaluate 
cardiovascular status. 
HEART FAILURE 
In more than 40 percent of patients there is a history suggestive of 
heart failure symptoms while starting dialysis; which is a significant factor 
for morbidity and mortality. Female sex, age, diabetes, atherosclerosis, 
structural cardiac abnormalities and pericarditis were associated with 
increased risk of heart failure in CKD patients. Patients those who are 
having left ventricular hypertrophy are associated with diastolic 
dysfunction. In uremia there is increased stiffness of left ventricle, so these 
patients will have diastolic dysfunction. There is also worsening of cardiac 
dysfunction in ESRD. 
LEFT VENTRICULAR HYPERTROPHY 
 It is an adaptive response occurring due to increased demand for 
myocardial work. 
 Becomes maladaptive due to the imbalance between energy 
expenditure and production, resulting in chronic energy deficient state 
and cardiac myocyte death. 
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 In CKD, there is combined pressure and volume overload due to Left 
Ventricular (LV) hypertrophy. 
 Pressure overload is due to sustained LV afterload because of 
hypertension, arteriosclerosis and aortic stenosis. 
 Volume overload is due to increased extracellular volume, anaemia 
and arterio-venous fistula. 
MANAGEMENT 
VOLUME OVERLOAD 
Because of risk of pulmonary edema, hypervolemia is life 
threatening in oliguric or anuric renal failure. Risk of pulmonary edema is 
very high if there is any previous lung disease. Fluids and salt should be 
restricted and diuretics may be useful. But increasing urine output does not 
alter the natural disease progression. In very severe volume overload, i.v 
bolus diuretics may be useful. If there is no response with bolus, we should 
stop diuretics. Sometimes low dose of dopamine may increase urine output. 
ELECTROLYTE AND ACID-BASE ABNORMALITIES 
No need to treat metabolic acidosis unless PH is less than 7.2 and 
serum bicarbonate <15mmol/L. Severe acidosis can be treated with oral or 
i.v sodium bicarbonate. Overcorrection of metabolic acidosis should be 
avoided, as this lead on to hypocalcemia, hypokalemia and metabolic 
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alkalosis. Hyperphosphatemia that is commonly seen in acute kidney injury 
can be treated with phosphate binders like sevelamer, calcium carbonate 
and aluminium hydroxide. Hypocalcemia that is seen in AKI does not 
require any treatment, unless patient is symptomatic. 
ANEMIA 
The anemia seen in AKI is usually not improved by erythropoiesis 
stimulating agents, because presence of bone marrow resistance and 
delayed onset of action. Bleeding seen in uremia may respond to 
desmopressin or estrogens. Sometimes dialysis may be required in uremic 
bleeding if uremia is severe or long standing. GI prophylaxis with PPI or 
H2 blockers is required. Venous thromboembolism prophylaxis is dose 
adjusted based on GFR. As factor Xa inhibitors and low molecular weight 
heparin have unpredicted response, they should be avoided in acute renal 
failure. 
DIALYSIS 
Various methods of dialysis available are (1) Peritoneal dialysis 
              (2)  Hemodialysis 
              (3)  Hemofiltration 
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PERITONEAL DIALYSIS  
Peritoneal dialysis uses the patient’s peritoneum as semipermeable 
membrane. Dialysate is instilled into the abdominal cavity. Initially it was 
used in clinically unstable patients. With the invention of continuous 
hemodialysis it is very rarely used for AKI. Now-a-days most common 
indication for peritoneal dialysis is ESRD. 
Two methods that are commonly used in peritoneal dialysis are  
1) Manual method 
2) Automated method 
 
 In manual exchange also called as continuous ambulatory peritoneal 
dialysis (CAPD) patient has to introduce the dialysate into the peritoneal 
cavity for a particular time period. After the specific time period the 
dialysate is drained and replaced with another volume of peritoneal fluid 
for dwell. 
 In automated method also called continuous cycling peritoneal 
dialysis (CCPD), usually performed at night where machine instills the 
dialysate into the peritoneal cavity at night as patient sleeps. Final fluid is 
kept in the abdomen for continuous solute exchange. 
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PRESCRIPTION OF PERITONEAL DIALYSIS: 
Choice between the two methods depends upon patient preference and 
characteristics of peritoneum. Following parameters must be mentioned in 
the prescription- 
 Volume of fluid- usually between 2-3 litres 
 Dwelling time 
 Concentration of dextrose- 1.5%, 2.5%, and 4.25%; higher 
concentration is needed to provide greater amount of fluid removal. 
But one of the main problems with high concentration solutions is 
absorption into circulation and worsening of the diabetes. Icodextrin, 
a glucose polymer can be used instead of dextrose, because it is 
poorly absorbed. 
Peritoneal dialysis is less effective than haemodialysis in clearing of solute. 
If used in large volume and frequent exchanges it may approximate other 
renal replacement therapies. Residual renal function is very important in 
peritoneal dialysis patients. 
 
COMPLICATIONS 
 
 Peritonitis- patient usually presents with diffuse abdominal pain and 
colour changes in the dialysate. If peritonitis is suspected, sample 
should be sent for culture and sensitivity, cell count and gram 
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staining. Total count of >100cells/cumm, with > 50% polymorphs 
supports the diagnosis of peritonitis. Empirical antibiotic therapy 
should be started with first generation cephalosporin (cefazolin or 
cephalothin) and ceftazidime. Dose is 15-20mg/kg in each of these 
drugs. Once culture results are obtained, then antibiotics are changed 
according to that. If multiple organisms are present intestinal 
perforation should be thought of. 
 Tunnel or exit site infections- patient may present with erythema, 
tenderness, and purulent discharge. Treatment with oral 
cephalosporin or oral fluroquinolone is needed. 
 Outflow failure- it may be due to kinking of the catheter, plugging of 
the catheter with fibrin or constipation. Mostly it is managed 
conservatively with relieving of constipation and instilling the 
dialysate with heparin in the dose of 500units/L. 
 Sclerosing encapsulating peritonitis- it is a one of the long term 
complication of the peritoneal dialysis. Peritoneum becomes 
thickened and encircles the small intestine and causes intestinal 
obstruction. It is mostly managed with bowel rest and if not resolved 
surgical lysis of adhesions. 
 Hyperglycaemia, hyperlipidaemia and hypokalaemia. 
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HEMODIALYSIS 
Most common form of renal replacement therapy employed in most of the 
renal injury situations. 
 Intermittent hemodialysis runs typically 2-4 hours per session and 
weekly three times. 
 Continuous renal replacement therapy (CRRT) - is used when patient 
hemodynamic status is unstable. Rate of blood flow is slow in this 
method, so anticoagulation is needed. 
 Sustained low efficiency dialysis is a hybrid variety of intermittent 
hemodialysis and continuous renal replacement therapy; usually 
done for 8 to hours per day. So patient can engage in other 
investigations, procedures and ambulation. 
PRESCRIPTION 
Intermittent hemodialysis typically runs for 3 to 4 hours. In the chronic 
setting weekly three times is enough. In acute setting adequacy of dialysis 
is assessed by URR (urea reduction ratio). 
URR= [pre dialysis urea-post dialysis urea /pre dialysis urea]*100 
Reduction of URR more than 65% is adequate for CKD. 
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COMPLICATIONS 
 Catheter related complications like infection, pneumothorax and 
bleeding. Tunneled catheters can be used up to 6 months. 
 Thrombosis of AV fistula or graft. This can be treated with 
thrombolysis, angioplasty or stent placement. 
 Intradialytic hypotension is mostly due to rapid ultrafiltration or 
depletion of intravascular volume. This can be managed with 
decreasing filtration rate and infusion of saline. 
 Dialysis disequilibrium syndrome is due to rapid removal of toxins; 
patients may develop nausea, vomiting, headache and seizure. 
RENAL TRANSPLANTATION 
Renal replacement therapy in the form of renal transplantation is the 
treatment of choice for end stage renal disease. For these, kidneys from 
living donor and brain dead patients can be used. Living donor grafts have 
survival rate of 95 percent in 1 year, when compared to deceased donor 
which has 89% in one year. In order to reduce the discard rates of kidneys 
expanded criteria donor (ECD) and donors after cardiac death (DCD) are 
used. Usually ECD kidneys are used in older patients, those who are doing 
less well on other methods of renal replacement therapy. 
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DEFINITION OF AN EXPANDED CRITERIA DONOR (ECD) 
 Deceased donor >60 years 
 Deceased donor >50 years and hypertension and creatinine >1.5 
mg/dL 
 Deceased donor >50 years and hypertension and death caused by 
cerebrovascular accident (CVA) 
 Deceased donor >50 years and death caused by CVA and creatinine 
>1.5 mg/dL 
NON-HEART-BEATING DONOR [DONATION AFTER CARDIAC 
DEATH (DCD)] 
 Brought in dead 
 Unsuccessful resuscitation 
 Awaiting cardiac arrest 
 Cardiac arrest after brainstem death 
 Cardiac arrest in a hospital patient 
RECIPIENT SELECTION 
Transplantation in patients who are on dialysis have a higher life 
expectancy than those who are remaining in dialysis alone. Mortality rate is 
higher in diabetic and older patients, but their survival rate is higher than 
the patients with dialysis alone. Every patient selected for dialysis should 
have risk benefit evaluation before transplantation. Absolute 
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contraindications for transplantation are HIV and active hepatitis, because 
of increased risk of opportunistic infection in these patients. Immunologic 
contraindications for transplantation are presence of preformed antibody in 
the donor. Antibodies causing early graft rejection are ABO blood group 
antigens and antibodies against human leukocyte antigen (HLA) class I (A, 
B, C) or class II (DR) antigens. These antibodies are routinely excluded by 
proper screening of the candidate's ABO compatibility, HLA typing of 
donor and recipient and direct cross-matching of candidate serum with 
lymphocytes of the donor. 
DONOR SELECTION 
Donors can be deceased or volunteer living donors. Living volunteer 
donors should be normal on physical examination and of the same major 
ABO blood group. It is possible to transplant a kidney of a type O donor 
into an A, B, or AB recipient. Selective renal arteriography should be 
performed on donors to rule out the presence of multiple or abnormal renal 
arteries because the surgical procedure is difficult and the ischemic time of 
the transplanted kidney is long when there are vascular abnormalities. 
Deceased donors should be free of neoplastic disease, hepatitis, and HIV 
because of possible transmission to the recipient. Increased risk of graft 
failure exists when the donor is elderly or has renal failure and when the 
kidney has a prolonged period of ischemia and storage. 
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IMMUNOSUPPRESSION 
Currently available immunosuppressive agents suppress all immune 
responses to fungus, malignant tumours and bacteria. 
Commonly used immune suppressive agents are 
1) Glucocorticoids 
Prednisone/prednisolone is generally used. It binds cytosolic 
receptors and heat shock proteins; Blocks transcription of IL-1,-2,-3,-
6, TNF-α, and IFN-γ. Side effects are hypertension, glucose 
intolerance, dyslipidaemia, and osteoporosis. 
2) Cyclosporine (CsA) 
It forms trimolecular complex with cyclophilin and calcineurin. It 
blocks cytokine (e.g., IL-2) production however it stimulates TGF-β 
production. Side effects are Nephrotoxicity, hypertension, 
dyslipidaemia, glucose intolerance and hirsutism/hyperplasia of 
gums. 
3) Azathioprine  
Hepatic metabolites of azathioprine inhibit purine synthesis. Side 
effect is marrow suppression (WBC > RBC > platelets). 
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4) Mycophenolate mofetil (MMF): It inhibits purine synthesis via 
inosine monophosphate dehydrogenase. Side effects are 
Diarrhoea/cramps and dose-related liver and marrow suppression. 
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CLINICAL COURSE AND MANAGEMENT OF THE RECIPIENT 
Adequate haemodialysis should be performed within 48 hours of 
surgery and care should be taken that the serum potassium level is not 
markedly elevated so that intraoperative cardiac arrhythmias can be 
prevented. Diuresis occurring in postoperative period, sometimes may be 
massive, due to inability of the tubules to concentrate urine. 
Acute tubular necrosis (ATN) may cause immediate oliguria or may 
follow an initial short period of graft function. ATN is most likely when 
cadaveric donors have been under perfused or if the interval between 
cessation of blood flow and organ harvest (warm ischemic time) is more 
than a few minutes. Recovery usually occurs within 3 weeks, although 
periods as long as 6 weeks have been reported. Superimposition of 
rejection on ATN is common, and the differential diagnosis may be 
difficult without a graft biopsy.  
Cyclosporine therapy prolongs ATN, and some patients do not 
diurese until the dose is reduced drastically. Many centres avoid starting 
cyclosporine for the first several days, using ALG or a monoclonal 
antibody along with mycophenolic acid and prednisone until renal function 
is established. 
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OPPORTUNISTIC INFECTION 
The most common opportunistic infections in renal transplant recipients 
are, 
Peritransplant (<1 month) 
Wound infections 
Herpes virus 
Oral candidiasis 
Urinary tract infection 
Early (1–6 months) 
Pneumocystis carinii 
Cytomegalovirus 
Legionella  
Listeria 
Hepatitis B 
Hepatitis C 
 Late (>6 months) 
Aspergillus  
Nocardia 
BK virus (polyoma) 
Herpes zoster 
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Hepatitis B 
Hepatitis C 
 
 OTHER COMPLICATIONS OF TRANSPLANTATION 
Myocardial infarction and stroke have higher incidence in chronic 
dialysis and transplant patients, particularly in diabetic patients. Other 
associated factors contributing to this increased incidence are use of 
glucocorticoids, sirolimus and hypertension. Cardiovascular system disease 
is contributing to more than 50% mortality in renal transplant recipients. So 
strict BP control and lipid profile monitoring is very important in this 
patients. 
GLOMERULAR FILTRATION RATE 
DEFINITION: 
Glomerular filtration rate is defined as volume of fluid filtered by the 
glomerular capillaries per unit time. It is expressed as ml/min/1.73m
2 
body 
surface area. Glomerular filtration rate is equal to clearance rate of the 
particular substance, when that particular substance is neither secreted nor 
absorbed from the tubular fluid. 
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NORMAL VALUES 
In men approximate level of glomerular filtration rate is 125 to 135 
ml/min/1.73m
2
 and in women the level is 115 to 125 ml/min/1.73m
2
. There 
is inter individual variability due to exercise, diurnal variation and protein 
intake. Gold standard substance that is used to measure GFR should have 
certain properties. They are free filterability across the glomerulus, no 
synthesis in the renal tubules, no reabsorption, not metabolized by the 
tubules and they should not alter the kidney function.  
INULIN 
Inulin is such a substance with most of the properties of ideal GFR 
measuring substance. It is a polymer of fructose, with molecular weight of 
5000 D. In original description inulin was infused as continuous 
intravenous infusion. Multiple blood and urine samples are taken during the 
procedure. Bladder was catheterised to measure exact amount of urine; 
sometimes oral intake of water is advised to stimulate diuresis. Inulin is 
very difficult to handle and also this procedure is time consuming and 
invasive. So in order to avoid these disadvantages, GFR estimating 
formulas are introduced. 
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CLEARANCE METHODS 
URINE CLEARANCE 
Creatinine clearance is a measurement of clearance of endogenous 
biomarker. Atleast 12 to 24 hour urine collection is needed for adequate 
urine sample and also to achieve steady state of concentrations of 
substances. Blood sample for creatinine estimation is collected usually at 
the end of urine collection period. Serum or urine cystatin C could not be 
used to measure clearance study due to its metabolism and reabsorption in 
renal tubules. 
PLASMA CLEARANCE 
In this method glomerular filtration rate is measured by clearance of 
that substance from plasma over a period of time. Clearance is calculated 
by amount of the substance injected divided by AUC of plasma 
concentration over time. One of the drawbacks of this method is time 
needed to determine the final point of curve. Sometimes it may be very 
difficult to get repeated blood samples for substance concentration 
estimation. 
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EXOGENOUS FILTRATION MARKERS 
Iothalmate 
It is used as nonradioactive form and radioactive form. If 
nonradioactive form is used high performance liquid chromatography is 
used to measure the concentration.  It is an iodine compound. If radioactive 
form is used it is given as subcutaneous injection. As it is an iodinated 
compound, to prevent thyroid uptake, cold iodine is also given along with 
iothalmate. Contraindication to its use is allergies to iodinated contrast. 
IOHEXOL 
Considering the hazards of the radioactive substances nonradioactive 
iohexol introduced. It can be given as bolus injection. Advantages of the 
iohexol over iothalmate are low cost, easy availability and stability in body.  
Adverse reactions are very low iohexol. One of the limitations is cost 
associated with high performance liquid chromatography. Some studies 
evaluated performance of this with other assay methods, which showed 
there is correlation between them.  
Technetium-99 labelled di-ethehylene triamino penta-acetic acid is also 
used to measure GFR. It is filtered across glomerulus completely. There is 
less radiation exposure with 99mTc. Very minimal plasma binding leads to 
underestimation of GFR. 
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ACCURATE MEASUREMENT OF GFR ESSENTIAL IN 
In most of the situations eGFR is enough to make decision about 
further planning. But in some clinical situations, glomerular estimation rate 
calculated based on serum creatinine is not that much accurate, so decision 
based on this inaccurate GFR leads to errors in patient management. So in 
some of situations, where estimation of glomerular filtration rate needed 
are, 
CHRONIC ILLNESS 
Because of reduced muscle mass in chronic illness, creatinine based 
equations measure inaccurate measurement of GFR. In these situations 
estimated GFR is inappropriately high when compared to measured-GFR. 
This may lead drug toxicity or kidney injury by contrast media. 
DRUG DOSE ADJUSTMENT 
If prolonged therapy and potential therapy is planned, we have to 
measure the glomerular filtration rate accurately. In most of the situations 
eGFR is enough, but if very toxic or very narrow therapeutic range drug 
should be used, it is better to measure GFR before starting treatment. 
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IMAGING TESTS 
As toxicity of the iodinated contrast material is high in the presence 
of reduced GFR, we have to measure glomerular filtration rate accurately 
before using these agents. Current guidelines are to avoid gadolinium and 
to take preventive measures before using iodinated contrast agents. 
MONITORING KIDNEY TRANSPLANT RECIPIENTS 
Early detection of rejection of transplanted kidney is very much 
challenging in renal transplantation setup. So eGFR results are very 
difficult to interpret. Also serum creatinine is affected by other than GFR; 
they are usage of trimethoprim, effect of steroids on muscle, protein intake. 
In this situation measurement GFR is needed. 
KIDNEY DONATION 
Modification of diet in renal disease study formula underestimates 
GFR, when compared to standard methods. So if eGFR is inappropriately 
low, in otherwise healthy renal donor, it is mandatory to do glomerular 
filtration rate measurement. 
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INTERPRETATION OF SYMPTOMS OF KIDNEY FAILURE 
Timing of access placement, pre-emptive transplantation and 
initiation of dialysis are generally determined based on an eGFR and 
patient symptoms. However, symptoms of uraemia are nonspecific. In 
patients with discrepancy between severity of reduction in eGFR and 
symptoms, it may be helpful to measure GFR. 
MATERIALS AND METHODS: 
STUDY POPULATION: 
This study was conducted in 100 adult patients in a medical Intensive Care 
Unit of Government Rajaji hospital Madurai. 
INCLUSION CRITERIA: 
1) ICU stay > 48 hours and <1 week 
2) Those with indwelling urinary catheter. 
EXCLUSION CRITERIA: 
1) Age less than 18 years 
2) Pregnancy 
3) Hemodialysis or peritoneal dialysis 
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4) Those on vasoactive drugs 
5) Urine output < 400 ml/day 
6) Patients receiving diuretics 
7) Not willing to give consent. 
DATA COLLECTION: 
As per the inclusion and exclusion criteria study subjects were 
selected. After obtaining detailed informed consent from the patient or 
patient’s attender if patient was illiterate, detailed history and physical 
examination was done. Blood and urine was collected from the subjects 
and the sample was sent to biochemistry lab for analysis. 
LABORATORY INVESTIGATIONS: 
1) Serum creatinine 
2) Blood urea 
3) 24 hours urine collection 
4) Urine creatinine concentration in 24 hours sample 
Serum creatinine and urine creatinine were measured by Jaffe’s 
calorimetric method. Body weight was measured in kilogram. Height of the 
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patient was measured in meters. Urine was collected from 8 Am to next 
day 8 Am.; first sample was discarded. Urine volume measured in ml/day. 
24 hours urine creatinine clearance was calculated by the following 
formula, 
Creatinine clearance (ml/min) = (U * V)/ (P*1440), then this was converted 
into body surface area by the using following formula 
CrCl= (U*V*1.73)/P*1440*BSA); here U is urine creatinine, V is urine 
volume in 24 hours, P is serum creatinine, BSA is body surface area. 
Body surface area was calculated by Du Bois formula 
Body surface area= Weight
0.425
*Height
0.725
*0.20247 
Here weight in kilograms, height in meters. 
 
ESTIMATED GLOMERULAR FILTRATION RATES 
1) Cockcroft- Gault formula 
EGFR = [(140-age) x (weight in Kg)] / [serum creatinine (mg/dl) x72] 
Multiplied by 0.85 if patient is female; GFR calculated by CG formula was 
converted to 1.73 m
2 
body surface area to compare with other two GFR.  
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2) MDRD estimated creatinine clearance (ml/min/1.73m2)  
EGFR = 186 x [serum creatinine (mg/dl)] ^
-1.154 
x (age in years) ^
-0.203 
If the subject or patient is female the GFR is multiplied by 0.742. 
STUDY PROTOCOL 
DESIGN OF STUDY: 
Prospective cross sectional study 
PERIOD OF STUDY:  4 months (JUNE 2014 TO SEPTEMBER 2014) 
COLLABORATING DEPARTMENTS: 
Department of Medicine 
Department of Biochemistry 
Department of Nephrology 
ETHICAL CLEARANCE: obtained. 
CONSENT: Individual written and informed consent. 
ANALYSIS:  statistical analysis 
Data collected from the patients were analyzed with help of 
Statistical software packages Medcalc® (version 8.1) from Medcalc® 
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Belgium. Bland Altman curve was used to evaluate the relationship 
between the two GFR calculating methods. The mean percentage 
difference between estimated and measured clearance called as bias is also 
calculated. Correlation coefficient was calculated to assess the association 
between two methods. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  NIL 
STUDY POPULATION 
100 adult patients from medical Intensive Care Unit of Government Rajaji 
Hospital, with atleast ICU stay of more than 48 hours. 
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RESULTS AND INTERPRETATIONS 
Table-1 age distribution of study population 
Age group 
 
Male n (%) Female n (%) Total n (%) 
10-20 years 
 
 
3 (3) 
 
1 (1) 4 (4) 
20-30 years 
 
 
11 (11) 
 
9 (9) 20 (20) 
30-40 years 
 
 
12 (12) 
 
10 (10) 22 (22) 
40-50 years 
 
 
13 (13) 
 
6 (6) 19 (19) 
50-60 years 
 
 
12 (12) 
 
9 (9) 21 (21) 
60-70 years 
 
 
10 (10) 
 
3 (3) 13 (13) 
70-80 years 
 
 
1 (1) 
 
0 (0) 1 (1) 
Total 
 
 
62 
 
38 100 
 
Comments: 
Study population selected for this study varies from the age of 19 years to 
71 years for male and from 19 years to 67 years for female. 65% of the 
study population belongs to the age group of <50 years. 35% of the study 
group belongs to the age group of >50 years. 
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Table-2: Descriptive statistics of age and sex distribution 
Variable  N   Mean     SD Minimum Median Maximum 
MALE 62 44.194 15.128  19.000 45.000  71.000 
FEMALE 38 41.421 13.912  19.000 37.500  67.000 
This study consists of 62 male patients and 38 female patients. 
Mean±SD of male patients are 44.194±15.128 and female patients are 
41.421±13.912; with median age of 45 and 37.5 for male and female 
patients respectively. 
Fig-7 Age distribution 
 
 
0
2
4
6
8
10
12
14
0 10 20 30 40 50 60 70 80 90 100
MALE
FEMALE
88 
 
Table-3 Sex distribution 
 
Fig-8 Sex distribution 
 
Comments:  
In this study 62% of the patients are male and remaining 38% are female 
SEX DISTRIBUTION 
MALE  -62%
FEMALE -38%
GENDER FREQUENCY PERCENT 
MALE 62 62 
FEMALE 38 38 
TOTAL 100 100 
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Fig-9 Descriptive statistics based on weight 
 
Comments: 
Minimum weight is 47kg and maximum weight is 78kg. Mean weight of 
the study population is 61.92kg with standard deviation of 7.021870596. 
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Fig-10 Height distribution of study population 
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Table-4 Epidemiological data of study population 
 
PARAMETER 
 
MEAN 
 
SD 
 
95% CI 
 
MINIMUM 
 
MAXIMUM 
Age(years) 43.14 14.67 40.23-46.05 19 71 
Weight(kg) 61.92 7.022 60.53-63.31 47 78 
Height(m) 1.621 0.06347 1.608-1.633 1.490 1.78 
S.creatinine (mg/dl) 
 
1.664 0.4398 1.577-1.751 0.8 2.5 
U.creatinine 
(mg/dl) 
 
63.06 11.75 60.73-65.39 50 98 
U.volume (ml) 
 
1518 307.5 1457-1579 850 2100 
BSA(m
2
) 1.657 0.1014 1.636-1.677 1.44 1.89 
 
Table-5 Mean and standard deviation comparison 
 
METHOD 
 
MEAN±SD 
 
MINIMUM 
 
MAXIMUM 
 
24 Hr Urine CrCl 
 
44.75±18.22 
 
20.89 
 
107.05 
 
CG FORMULA 
 
56.48±20.30 
 
26.89 
 
131.16 
 
MDRD 
 
48.71±19.69 
 
23.16 
 
115.54 
Comments:  
Mean±SD of the three methods are 44.75±18.22, 56.48±20.30, 
48.71±19.69 respectively. 
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Table-6 Pearson correlation coefficient 
 
 
METHOD 
 
BIAS 
 
CORRELATION 
COEFFICIENT 
 
P VALUE 
 
CG/ 24 Hr Urine 
CrCl 
 
11.73 
 
0.9056 
 
<0.0001 
 
MDRD/ 24 Hr 
Urine CrCl 
 
3.961 
 
0.9303 
 
<0.0001 
 
Comments: 
Both Cockcroft-gault and MDRD formula have positive bias 11.73 and 
3.961 respectively, so both these formulas overestimate the glomerular 
filtration rate. Correlation coefficient for comparison of Cockcroft-Gault 
formula and 24 hour urine creatinine clearance is 0.90956 with p value of 
<0.0001. It indicates strong correlation between GFR calculated by 
Cockcroft-Gault formula and GFR measured by 24 hours urine creatinine 
clearance. Correlation coefficient for comparison between GFR calculated 
by MDRD formula with 24 hour urine creatinine clearance is 0.9303 with p 
value of <0.0001. It means there is strong correlation between GFR 
calculated by MDRD formula and GFR measured by 24 hours urine 
creatinine clearance. 
92 
 
Fig-11 Pearson correlation coefficient analysis 
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Comments: 
This shows correlation between GFR calculated by Cockcroft-Gault 
method and 24 hour urine creatinine clearance.  
 r (correlation coefficient) = 0.9056 
95% confidence interval 0.8626 – 0.9356 
P value <0.0001 
CG & 24 HOUR CREATININE CLEARANCE 
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Fig-12 Bland- Altman correlation analysis. 
5 0 1 0 0 1 5 0
-2 0
-1 0
0
1 0
2 0
3 0
4 0
D if fe r e n c e  v s . a v e r a g e :  B la n d -A ltm a n  C o r r e la t io n  o f  C r C L  w ith  C G
A v e r a g e
D
if
f
e
r
e
n
c
e
 
 
 
Comments: 
Bias = 11.73 
SD of bias 8.612 
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Fig-13 Pearson correlation coefficient analysis 
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Comments: 
This shows correlation between GFR calculated by MDRD method and 24 
hour urine creatinine clearance.  
 r (correlation coefficient) = 0.9303 
95% confidence interval 0.8979 – 0.9526 
P value <0.0001 
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Fig-14 Bland Altman correlation analysis  
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Comments: 
Bias = 3.961 
SD of bias 7.225 
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DISCUSSION 
This study was conducted in intensive care unit of Government 
Rajaji hospital Madurai. Patients with age more than 18 years of age were 
included. Pregnant patients and patients on renal replacement therapy were 
excluded from the study. 100 patients were selected for GFR comparison 
study. Period of study was 4 months. 
AGE AND SEX DISTRIBUTION OF THE STUDY 
In this study mean age group of patients were 43.14 with standard 
deviation of 14.67; minimum age of the patient was 19 years and maximum 
age of the patient was 71 years. Out of 100 patients male patients were 62 
and female patients were 38. (95% confidence interval for age was 40.23-
46.05).
table 1
  
In a study conducted by Mohit Kharbanda et al from Departments of 
Critical Care and Nephrology, AMRI Hospitals, Kolkata, India; mean age 
group was 65 years with 95% confidence of 58 to 68 years. Another study 
conducted by Magdi E. Al-Osali et al from Department of Internal 
Medicine, Al Nahdha Hospital, and Muscat, Oman included 158 patients; 
in this 115 patients belongs to age group of <70 years and 43 were >70 
years. 
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In our study Mean±SD serum creatinine was 1.664±0.4398 (95% 
confidence interval 10557-1.751). In a study conducted by Mohit 
Kharbanda et al from Departments of Critical Care and Nephrology, AMRI 
Hospitals, Kolkata, India, mean serum creatinine was 1.06 mg/dl (95% CI 
0.76 to 1.37. In another study conducted by Adnan Mustafa Zubairi et al 
from department of Clinical Pathology, Ziauddin University, Karachi in 
2008 also showed Mean ±SD of 1.94 ± 1.55. 
MEAN GFR AND CORRELATION COMPARISON 
Estimation of glomerular filtration rate is important to decide about 
patient management, renal replacement therapy, and while administering 
drugs that is eliminated through kidney. In order to avoid toxicities of the 
drugs we have to monitor renal function by estimating glomerular filtration 
rate. This is very much important in ICU because, patient may get multiple 
drugs with different metabolic route for elimination. Glomerular filtration 
rate is the one of the best measure of kidney function. It can be measured 
by clearance of the exogenous substance. But these methods are costly and 
not easily available in hospitals. Endogenous substances such as creatinine 
also can be used to measure GFR, but it is affected by muscle mass, protein 
intake and exercise. In order to avoid these problems researchers found 
equations based on serum creatinine, body weight and age. Commonly 
used formulas are Cockcroft-Gault and MDRD formula. In this study we 
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compared the GFR measured by 24 hour urine creatinine clearance with 
CG and MDRD formula. There are some advantages with these formulas; 
they are simple, easy and repeatability.  
The mean glomerular filtration rate measured by 24 hours urine 
creatinine clearance was 44.75ml/min/1.73m
2
 (95% CI: 41.13 to 48.37). 
The mean glomerular rate calculated by Cockcroft-Gault formula was 
56.48ml/min/1.73m
2 
(95%CI: 52.45 to 60.51) and by MDRD formula was 
48.71ml/min/m
2 
(95% CI: 44.80 to 52.62).
Table 5
 Correlation coefficient for 
comparison of Cockcroft-Gault formula and 24 hour urine creatinine 
clearance is 0.90956 with p value of <0.0001. Correlation coefficient for 
comparison between GFR calculated by MDRD formula with 24 hour urine 
creatinine clearance is 0.9303 with p value of <0.0001
Table 6
.
 
However application of these formulas to calculate GFR, leads to 
overestimation of GFR as shown by positive Bias. In our study which is 
11.73ml/min for Cockcroft-Gault equation and 3.961ml/min for MDRD 
equation
Table 6
. In a study conducted by Adnan Mustafa Zubairi et al from 
department of Clinical Pathology, Ziauddin University, Karachi showed 
bias of 16.5ml/min and 15.49ml/min for CG formula and MDRD formula 
respectively. In another study conducted by Mohit Kharbanda et al from 
Departments of Critical Care and Nephrology, AMRI Hospitals, Kolkata 
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also showed positive bias of 10.3ml/min and 5.2ml/min for CG and MDRD 
equations respectively. 
LIMITATIONS OF THE STUDY 
In this study we did not compare eGFR with gold standard methods 
such as inulin or iohexol clearance. In developing countries 24 hour urine 
creatinine clearance is used as a gold standard for GFR measurement. In 
the year 2005 Vila et al termed it as a gold standard. Serum creatinine is the 
net result of production, distribution, glomerular filtration, tubular 
secretion, and tubular re-absorption. Major source of creatinine is from 
metabolism of muscle. In critically ill patients creatinine production is 
decreased due to decreased intake of protein and reduced muscle mass. 
This decreased production may be one of the reasons for over estimation of 
glomerular filtration rate by serum creatinine based equations. So in 
critically ill patients, serum creatinine poorly reflects the change of 
glomerular filtration rate.  
As inulin and other clearance studies are usually not available, we 
have to rely upon these eGFR formulas for glomerular estimation; this was 
conducted in the usual clinical setting. Even though these formulas 
overestimated the glomerular filtration rate, there is strong correlation 
between the formulas and 24 hours creatinine clearance. 
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CONCLUSION 
As age, muscle mass, drugs, protein intake, exercise and sex affects 
the serum creatinine level it does not reflect the accurate renal function. 
And also as serum creatinine level lies within normal range till significant 
amount kidney function is lost, serum creatinine cannot be used to detect 
mild to moderate amount of renal dysfunction. Thus normal range of serum 
creatinine does not rule out kidney disease. GFR estimation is the main 
important step in assessing the renal function. In this study both CG and 
MDRD formulas have good correlation with 24 hour urine creatinine 
clearance. Because of convenience and cost, they can be used to assess the 
progression of disease. In clinical practice they have to interpret carefully 
because they tend to overestimate the actual glomerular filtration rate. 
Before applying into patients it is recommended that the study is to be 
conducted in large group of patients belonging to all ethnic groups.  
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SUMMARY 
 In the intensive care setting estimation of glomerular filtration rate is 
important because, planning about treatment, renal replacement therapy, 
and deciding about drug dosage all depends upon the GFR. 
 Originally substance that has been used should be filtered freely, neither 
reabsorbed nor secreted. Inulin is such substance, but it is not easily 
available. 
 24 hours urine creatinine clearance may be used, but we have to wait for 
24 hours to get the report. Also some amount of tubular secretion leads 
to inappropriately high clearance. 
 So formulas were developed to calculate eGFR that may be used in 
clinical situation to decide about treatment plan. These formulas are easy 
to apply and easily reproducible. 
 Cockcroft-Gault and MDRD formulas are such formulas commonly used 
in clinical practice. 
 Except one or two studies, no other studies evaluated it in Indian 
patients. So we compared these formulas with 24 hour urine creatinine 
clearance in estimating glomerular filtration rate. 
 This study was conducted in 100 critically ill adult patients of 
Government Rajaji Hospital. For all patients 24 hour urine creatinine 
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clearance was measured and eGFR estimated by both CG and MDRD 
formulas. 
 Bland Altman analysis and Pearson correlation coefficient was 
calculated. 
 The mean GFR measured by 24 hours urine creatinine clearance was 
44.75ml/min/1.73m2 (95% CI: 41.13 to 48.37). The mean glomerular 
rate calculated by Cockcroft-Gault formula was 56.48ml/min/1.73m2 
(95%CI: 52.45 to 60.51) and by MDRD formula was 48.71ml/min/m2 
(95% CI: 44.80 to 52.62). 
 Correlation coefficient for comparison of CG formula/24 hour urine 
creatinine clearance and MDRD/24 hour urine clearance were 0.90956 
with p value of <0.0001 and 0.9303 with p value of <0.0001 
respectively. 
 Both formulas had strong correlation with urine clearance. But MDRD 
had better correlation than CG formula. 
 Bias is defined as the mean difference between calculated and measured 
GFR. 
 In our study bias was 11.73ml/min for Cockcroft-Gault equation and 
3.961ml/min for MDRD equation. 
 It indicates over estimation of GFR by both these formulas when 
compared to 24 hour urine creatinine clearance.  
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PROFORMA 
 
Name:                        
 
Age/Sex:                             
 
Occupation: 
 
Past history: 
 
Drug history: 
 
Family history: 
 
Clinical examination: 
 
General examination: 
1)Height 
 
2)weight 
 
3)BMI 
 
 
Vitals: 
PR- 
BP- 
RR - 
SpO2- 
 
Systemic examination:  
CVS:  
 
RS:  
 
ABDOMEN:  
 
CNS: 
 
Laboratory investigations: 
1) Serum creatinine 
2) Blood urea 
3) 24 hours urine collection 
4) 1 hour urine collection 
5) Urine creatinine concentration in 1 hour sample 
6) Urine creatinine concentration in 24 hours sample 
ABBREVIATIONS 
GFR- Glomerular Filtration Rate 
DTPA- Diethyl Triamine Penta-Acetic Acid 
EDTA- Ethylene Diamine Tetraacetic Acids 
MDRD- Modification of Diet in Renal Disease 
CG- Cockcroft Gault 
AKI- Acute Kidney Injury 
CKD- Chronic Kidney Disease 
VEGF- Vascular endothelial growth factor 
JG- Juxta glomerular apparatus 
RAAS- Renin angiotensin aldosterone system 
ADH- Antidiuretic hormone 
ACE- Angiotensin converting enzyme 
ARB- Angiotensin receptor blocker 
ANA- Antinuclear antibody 
ANCA- Antinuclear cytoplasmic antibody 
ADPKD- Autosomal polycystic kidney disease 
KDOQI- Kidney disease outcome quality initiative 
NKF- National kidney foundation 
CAPD- Continuous ambulatory peritoneal dialysis 
CCPD- Continuous cycling peritoneal dialysis 
CRRT- Continuous renal replacement therapy 
ECD- Expanded criteria donor 
DCD- Donors after cardiac death 
ATN- Acute tubular necrosis 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
S.NO AGE SEX WT HT Scr U.CR U Volume BSA CrCL MDRD CG/1.73 
1 32 M 63 1.68 1.8 52 1763 1.72 35.66 46.71 52.9 
2 52 M 52 1.62 2.3 56 1100 1.54 20.89 31.90 31.0 
3 45 M 67 1.58 0.9 55 1950 1.68 84.99 96.99 100.9 
4 63 M 58 1.67 2.2 55 1575 1.65 28.68 32.29 29.6 
5 48 M 67 1.72 1.9 50 2100 1.79 37.06 40.41 43.5 
6 25 M 59 1.63 1.7 78 1750 1.63 59.10 52.46 58.7 
7 54 M 59 1.54 1.8 52 1600 1.57 35.45 42.00 43.2 
8 67 M 58 1.59 1.6 54 1400 1.59 35.67 46.05 39.9 
9 21 M 48 1.72 1.9 63 1280 1.55 32.80 47.80 46.5 
10 34 M 65 1.67 1.7 65 1700 1.73 45.11 49.28 56.3 
11 19 M 54 1.62 1.5 85 1550 1.57 67.42 64.08 66.9 
12 47 M 68 1.7 2 54 1875 1.79 34.02 38.26 42.5 
13 35 M 57 1.66 2.1 58 1325 1.63 26.97 38.39 42.0 
14 39 M 74 1.65 1.3 51 2100 1.81 54.58 65.32 76.2 
15 65 M 69 1.59 0.9 53 1980 1.71 81.75 90.01 80.6 
16 49 M 64 1.62 1 51 1750 1.68 63.74 84.41 83.2 
17 57 M 68 1.63 1.1 75 1800 1.73 85.04 73.33 71.1 
18 33 M 64 1.57 1.8 55 1965 1.64 43.87 46.42 55.6 
19 68 M 69 1.55 2 73 1400 1.68 36.50 35.49 35.5 
20 48 M 71 1.64 2.1 74 1350 1.77 32.22 36.01 42.1 
21 59 M 65 1.69 1.2 58 1450 1.75 48.22 65.87 60.4 
22 57 M 65 1.64 1.1 75 1150 1.71 55.14 73.33 69.0 
23 65 M 67 1.67 1.9 68 1250 1.75 30.65 38.00 36.2 
24 19 M 70 1.59 0.9 68 1950 1.72 102.6 115.54 131.2 
25 64 M 62 1.72 1.4 58 1560 1.73 44.79 54.23 46.7 
26 28 M 61 1.78 1.5 60 1840 1.76 50.10 59.23 62.0 
27 35 M 65 1.54 1 79 1650 1.63 95.94 90.38 100.5 
28 41 M 58 1.68 2.5 55 1900 1.66 30.32 30.40 33.3 
29 28 M 63 1.66 2 52 1750 1.70 32.14 42.50 49.8 
30 65 M 71 1.62 1.7 72 1665 1.76 48.19 43.21 42.8 
31 32 M 68 1.74 1.6 88 1900 1.82 69.06 53.51 60.7 
32 58 M 64 1.67 1.4 57 1650 1.72 46.93 55.32 52.4 
33 25 M 55 1.59 1.8 78 1400 1.56 46.84 49.11 54.3 
34 39 M 57 1.64 1.5 54 1300 1.62 34.80 55.38 57.1 
35 47 M 69 1.68 1.7 53 1900 1.78 39.91 46.15 50.9 
36 38 M 67 1.75 1.6 56 1750 1.81 40.56 51.67 56.6 
37 21 M 54 1.7 1.2 67 1650 1.62 68.29 81.23 79.4 
38 29 M 62 1.59 2.2 58 1865 1.64 36.08 37.80 45.9 
39 54 M 69 1.52 1 64 1690 1.66 78.35 82.76 86.0 
40 46 M 57 1.69 2.1 63 1700 1.65 37.10 36.32 37.1 
S.NO AGE SEX WT HT Scr U.CR U Volume BSA CrCL MDRD CG/1.73 
41 35 M 68 1.62 1.6 51 1980 1.73 43.93 52.54 62.1 
42 19 M 67 1.65 0.9 68 2050 1.74 107.0 115.54 124.5 
43 27 M 69 1.58 2.2 61 2100 1.71 41.01 38.35 49.9 
44 55 M 78 1.57 1.4 68 1386 1.79 45.22 55.92 63.6 
45 48 M 67 1.68 1.6 53 1210 1.76 27.34 49.28 52.6 
46 58 M 65 1.64 2.1 85 1100 1.71 31.31 34.65 35.7 
47 54 M 68 1.63 1.7 90 1250 1.73 45.85 44.86 47.7 
48 39 M 64 1.55 2.4 59 1450 1.63 26.29 32.19 39.7 
49 51 M 74 1.75 1.4 64 1800 1.89 52.24 56.79 59.7 
50 24 M 69 1.73 1.7 55 1870 1.82 39.90 52.89 62.1 
51 44 M 65 1.69 2.3 75 1565 1.75 35.11 33.00 37.3 
52 28 M 58 1.57 2.1 94 1100 1.58 37.51 40.17 47.1 
53 64 M 67 1.67 1.4 51 1650 1.75 41.18 54.23 49.8 
54 71 M 54 1.66 1.9 51 1870 1.59 37.86 37.33 29.6 
55 45 M 58 1.53 2.3 69 1350 1.55 31.44 32.85 37.2 
56 57 M 75 1.58 1.7 51 1550 1.77 31.61 44.37 49.8 
57 33 M 58 1.73 1.4 55 1725 1.69 48.12 62.03 63.0 
58 21 M 68 1.76 1 90 1375 1.83 81.11 100.25 106.1 
59 65 M 59 1.65 1.7 65 1260 1.65 35.15 43.21 38.0 
60 42 M 67 1.63 2.4 54 2000 1.72 31.38 31.71 38.2 
61 68 M 69 1.67 2.5 55 1900 1.78 28.28 27.43 26.9 
62 41 M 64 1.63 1.1 75 1480 1.69 71.74 78.41 81.9 
63 35 F 58 1.51 1.7 51 1560 1.53 36.67 36.35 56.1 
64 23 F 49 1.53 1.5 53 1400 1.44 41.25 45.74 63.7 
65 24 F 57 1.49 2.1 68 1650 1.51 42.59 30.75 50.2 
66 36 F 49 1.61 1 65 1250 1.50 65.29 66.68 81.9 
67 28 F 53 1.64 1.9 69 1300 1.57 36.21 33.46 47.9 
68 19 F 50 1.58 2.1 51 1650 1.49 32.36 32.25 46.5 
69 65 F 64 1.57 2.2 63 1450 1.64 30.34 23.81 31.9 
70 54 F 47 1.59 1.7 72 900 1.46 31.46 33.29 39.3 
71 45 F 68 1.6 1 60 1560 1.71 65.73 63.73 90.7 
72 46 F 52 1.57 0.8 58 1400 1.51 81.00 82.08 97.5 
73 58 F 65 1.63 1.1 62 1375 1.70 54.74 54.22 68.4 
74 57 F 57 1.65 1.2 57 1300 1.62 45.71 49.22 58.4 
75 35 F 58 1.58 2.1 81 1100 1.58 32.17 28.49 44.0 
76 21 F 55 1.63 1.9 98 850 1.58 33.24 35.47 52.2 
77 26 F 51 1.57 2.4 75 1200 1.49 30.17 25.94 39.0 
78 58 F 63 1.55 1.4 59 1300 1.62 40.67 41.05 54.8 
79 56 F 68 1.6 1.6 72 1100 1.71 34.76 35.44 50.1 
80 54 F 72 1.59 1.5 58 1250 1.74 33.28 38.46 56.8 
81 36 F 57 1.58 2.5 83 1000 1.57 25.36 23.16 36.2 
82 24 F 56 1.62 2 55 1475 1.59 30.66 32.53 49.1 
83 67 F 49 1.53 1.9 64 950 1.44 26.68 28.02 31.4 
 S.NO AGE SEX WT HT Scr U.CR U Volume BSA CrCL MDRD CG/1.73 
84 54 F 57 1.54 1.5 71 975 1.54 35.92 38.46 50.9 
85 35 F 62 1.54 1.8 85 1250 1.60 44.33 34.03 54.3 
86 31 F 63 1.59 1.6 58 1800 1.65 47.55 39.96 62.6 
87 46 F 49 1.61 1.4 51 1375 1.50 40.25 43.03 52.9 
88 48 F 69 1.54 1.5 58 1250 1.67 34.68 39.39 60.7 
89 56 F 67 1.57 1.8 50 1300 1.68 25.87 30.94 44.8 
90 34 F 53 1.52 2.3 53 1325 1.48 24.74 25.80 39.6 
91 28 F 54 1.53 2 57 1200 1.50 27.36 31.53 48.4 
92 65 F 47 1.57 1.4 50 1275 1.44 37.93 40.11 41.9 
93 47 F 65 1.65 1.9 51 1560 1.72 29.32 30.12 44.5 
94 39 F 58 1.57 1.8 83 975 1.58 34.25 33.29 49.6 
95 35 F 61 1.58 1 51 1650 1.62 62.46 67.06 95.1 
96 26 F 67 1.65 1.9 67 1400 1.74 34.12 33.96 55.6 
97 27 F 58 1.61 1.7 59 1300 1.61 33.75 38.32 57.7 
98 47 F 67 1.67 0.9 50 1950 1.75 74.22 71.33 94.9 
99 34 F 55 1.57 1.2 52 1650 1.54 55.71 54.66 75.7 
100 55 F 68 1.54 1.4 55 1200 1.66 34.04 41.49 59.6 
 
  
 
 
 
  
 
 
